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Summary
Insulin detemir has a 14 C fatty acid chain, which associates with free fatty acid binding 
sites on albumin. Capillary endothelial cells in adipose tissue and muscle may limit transfer 
of insulin detemir from the circulation into the extravascular extracellular space. In the 
liver, the open sinusoids may expose hepatocytes to insulin detemir enabling it to have 
greater effect on the liver than on the periphery.
We investigated the effects of two doses of insulin detemir and one dose of NPH insulin on 
hepatic glucose output (Ra), peripheral glucose uptake (Rd), glycerol Ra using stable isotope 
techniques and on NEFA, IGF-1, IGFBP-1, C-peptide, and glucagon concentrations in 7 
healthy volunteers, 6 volunteers with type 1 diabetes and 6 volunteers with type 2 diabetes 
during a 16h euglycaemic clamp.
In healthy volunteers we demonstrated that 9nmol/kg insulin detemir had greater effect on 
suppression of glucose Ra than an equipotent dose of NPH (0.3iu/kg or 1.8nmol/kg). In 
subjects with type 1 and type 2 diabetes 18nmol/kg insulin detemir was equipotent to 0.6 
iu/kg (3.6 nmol/kg) NPH, with a similar time action profile. In subjects with type 1 diabetes 
we were unable to demonstrate differences in the effect of insulin detemir on glucose Ra but 
demonstrated small but significant differences in effect on glucose Rd compared to the 
equipotent dose of NPH. The suppression of NEFA concentrations by insulin detemir was 
less than with an equipotent dose of NPH, both in healthy subjects and to a lesser extent in 
those with type 1 diabetes. We were unable to demonstrate a statistical difference in effect 
on glucose or lipid metabolism in subjects with type 2 diabetes. There were no differences 
in the effect of these two insulins on glycerol Ra, IGF-1, IGFBP-1, glucagon or c-peptide 
concentrations in any of our three subject groups. We demonstrated a dose response effect 
for insulin detemir.
This study suggests that when equipotent doses of insulin detemir are compared to NPH 
insulin, detemir has greater effect on the liver than peripheral tissues and thus the potential 
to restore the normal insulin gradient.
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Chapter 1
Introduction
Diabetes 
Definition
Diabetes mellitus is a state of chronic hyperglycaemia, classically associated with symptoms 
of excessive thirst, increased urine volume and weight loss. It results from the insufficiency 
of or diminished effectiveness of endogenous insulin.
Classification of diabetes (American Diabetes Association 1999)
I Type 1 diabetes (P-cell destruction, usually leading to absolute insulin deficiency)
A. Immune mediated
B. Idiopathic
II Type 2 diabetes (ranging from predominantly insulin resistance with relative insulin 
deficiency to predominantly an insulin secretory defect with insulin resistance).
III Other specific types of diabetes
A. Genetic defects of P-cell function
B. Genetic defects of insulin action
C. Diseases of the exocrine pancreas
D. Endocrinopathies
E. Drug or chemical induced
F. Infections
G. Uncommon forms of immune mediated diabetes
H. Other genetic syndromes sometimes associated with diabetes.
IV Gestational diabetes
Criteria for the diagnosis of diabetes mellitus
I. Symptoms of diabetes plus casual plasma glucose concentration >200mg/dl 
(11.1 mmol/1). Casual is defined as any time of day without regard to time since last meal. 
The classic symptoms of diabetes include polyuria, polydipsia and unexplained weight loss.
13
Or
2. Fasting plasma glucose > 126mg/dl (7.0mmol/l). Fasting is defined as no calorie intake 
for at least 8 hours.
Or
2-hour plasma glucose >200mg/dl (11.1 mmol/1) during an OGTT. The test should be 
performed as described by WHO, using a glucose load containing the equivalent of 75mg 
anhydrous glucose dissolved in water.
In the absence of unequivocal hyperglycaemia with acute metabolic decompensation, these 
criteria should be confirmed by repeat testing on a different day.
Epidemiology
The world-wide incidence of type 1 diabetes varies greatly from as high as 36 per 100 000 
per year in some Scandinavian countries while in countries such as Japan it is only 2 per 100 
000 per year, Venezuela has the lowest recorded incidence of 0.1 per 100 000 per year 
(Wareham, 2002). The disease is predominantly one of white Caucasian populations and is 
relatively rare in both oriental and black populations (Bell and Hockaday, 1996). The 
incidence of type 1 diabetes appears to be increasing. Increases have been reported in 
Scotland of about 2 % per annum during the period 1984-1993 (Rangasami et al, 1997). 
The overall pooled incidence in 37 countries was 3% per year, the increase was relatively 
greater in populations with the lowest incidence. The incidence of type 1 diabetes also 
varies with season, being highest in autumn and winter. Type 1 diabetes incidence varies by 
age and sex, with in the UK the peak incidence in boys being at 12-13 years and the peak 
incidence in girls being 9-12 years. The incidence is slightly higher in boys than girls (Ratio 
1.08: 1). (Wareham, 2002)
Type 2 diabetes is far more common than type 1. In some populations of Polynesian- 
Micronesian stock the prevalence may be as high as 40-50%, whether on affluent Pacific 
islands (eg Nauru) or in reservations in Arizona (Pima Indians). The prevalence in the 
United Kingdom was believed to be 2%. However recent studies have suggested values
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ranging from 8 to 12% depending on ethnic mix (Bell and Hockaday, 1996). There are 
currently believed to be 1 million people in the UK with undiagnosed diabetes (Diabetes 
UK). The prevalence of type 2 diabetes is lowest in rural areas of developing countries, is 
generally intermediate in developed countries and is highest in some ethnic groups who have 
adopted Western lifestyle patterns. The populations with the highest prevalence (Pima 
Indians and Nauruans) have a high prevalence of obesity. It is hypothesized that genetic 
susceptibility to obesity in these populations would be disadvantageous in times of food 
abundance, but would give evolutionary advantages at times when food is scarce, giving 
rise to increased prevalence of the gene by natural selection. This “thrifty genotype” 
hypothesis is supported by evidence of gene environment interaction -  individuals who 
migrate from low prevalence areas to the West are at increased risk of type 2 diabetes. The 
prevalence of type 2 diabetes is also increasing with figures from the USA showing a 33% 
increase in prevalence from 4.9% in 1990 to 6.5% in 1998 (Mokdad et al, 2000). This 
increase in prevalence mirrors the increasing prevalence of obesity. The main aetiological 
risk factors for type 2 diabetes are age, obesity, family history, physical inactivity and 
dietary factors such as a high proportion of energy consumed as saturated fat and low intake 
of finit and vegetables. (Wareham, 2002)
History of diabetes.
Early Hindu writings attributed to Susrata in 400BC, describe people with a mysterious and 
deadly disease that caused increased thirst, enormous urine output and wasting away of the 
body whose urine was attractive to black ants. (MacCracken, 1997, Owens, 1986). Areteus 
of Cappadocia a contempory of Nero (30-90 AD) wrote “diabetes is a strange disease, 
which fortunately is not very frequent. It consists o f the flesh and bones running together 
into the urine.... The illness develops very slowly. Its final outcome is death... The patients 
are tortured by an unquenchable thirst; they never cease drinking and urinating.... The 
disease was called diabetes, as though it were a siphon because it converts the human body 
into a pipe for the transflux o f liquid humors. Now since the patient goes on drinking and 
urinating while only the smallest portion o f what he drinks is assimilated in the body, life 
naturally cannot be preserved fo r  very long, fo r a portion o f the flesh is also excreted
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through the urine.” (Hoskins, 1941). The term diabetes (from Greek Dia, through and 
baino, I flow and mellita, a bee) had actually been coined earlier by Apollonius of Memphis 
and Demetrius of Apamea around 250 BC.
It wasn’t until 1674 that Thomas Willis re-described the presence of glycosuria and 
concluded that this must be preceeded by presence of sweetness in the blood. In 1774 
Matthew Dobson demonstrated that the sweetness of urine and serum was due to sugar. In 
1849 Claude Bernard working on glucagon metabolism in the liver linked diabetes with 
glycogen metabolism. In 1869 Paul Langerhans, then 22 described small bodies in the 
pancreas in his thesis in Berlin. Unfortunately he was unable to continue his work, 
developing tuberculosis, he had to leave Germany to live in Madeira, where he died at the 
age of 40 (Andreani, 1999).
In the late 19 Century Minkowski and von Mehring were interested in the study of the 
pancreas in relation to digestion. However it was a kennel worker who was caring for the 
experimental animals of the two doctors who noticed that their urine was attracting great 
swarms of flies, he drew the doctor’s attention to this whereupon it was discovered the urine 
had large amounts of sugar (Minkowski later denied this version of events). Thus 
experimental diabetes had been produced. Minkowski recognised the significance of the 
discovery and tried to make an extract of dog’s pancreas that would have a beneficial effect 
on the experimental diabetes he had produced but without success. Caparelli however 
anticipated him and discovered a simple saline extract of pancreas injected directly into the 
abdominal cavity of dogs had a marked lessening or even disappearance of glucose in the 
urine.
Clinicians immediately attempted to use the knowledge, some administered fresh pancreas 
by mouth, some gave juice expressed from the gland, and some administered extracts 
rectally. Bormann administered roast pancreas by mouth, later infusions by rectum and 
finally subcutaneous injections of raw pancreas extract. One of his patients who received 
the latter treatment gained eight pounds in six weeks. Others were finding similar results 
however these pancreatic extract contained digestive enzymes and patients were unable to
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tolerate the injections for long (Hoskins, 1941). In 1898 Blumenthal squeezed the juice 
from raw pancreas and treated it with alcohol to remove the protein. When administered 
intravenously it killed his experimental animals, and when injected subcutaneously caused 
ulcers however he was able to show that subcutaneous injection of his preparation increased 
glucose utilization by 40%. Blumenthal was actually using a crude preparation o f insulin, 
and had his side effects been less severe he may have enjoyed some of the glory given to 
workers a quarter of a century later.
The next ten years revealed little hope for the treatment of diabetes, indeed “The Household 
Physician” “A family guide to the preservation of health and to the domestic treatment of 
ailments and disease” (McGregor-Robertson, 1898) wrote that the chief treatment consisted 
of regulation of the diet. It gives two tables of permitted and not permitted foods and drinks 
and also recommended that the patient “take regular moderate exercise, flannels should be 
worn, and warm baths taken frequently”. Of pharmacological approaches to treatment its 
author wrote, “many medicines have been tried, but none have been very successful. Opium 
and ergot are probably the best, and may be taken in pill containing % grain powdered 
opium and 2 grains ergotine, one thrice daily. In many cases the use o f  opium ought be 
pushed but not without medical supervision.” In 1913 Frederick Allen wrote “all 
authorities are agreed upon the failure ofpancreatic opotherapy in diabetes ...injections o f  
pancreatic preparations have both proved useless and harmful. The failure began with 
Minkowski and has continued to the present without interruption... The negative reports 
have been numerous and trustworthy. ” (Allen, 1913).
Frederick Madison Allen (bom in 1876) working at Harvard Medical school, carried out 
extensive work on diabetes and carbohydrate metabolism. He concluded that while diabetes 
was mostly a problem of carbohydrate metabolism, it was not just the carbohydatres but the 
proteins and fats as well. Diets that involved cutting back sharply on carbohydrates and 
increasing proteins and fats achieved little and if  anything caused a deterioration in the 
condition with a higher rate of acidosis and death resulting from the metabolism of fats. 
Described as a stem, cold, tireless scientist (Bliss 1982) Allen had a ward of diabetic 
patients at the Rockefeller Institute in New York. Here he applied his diets to an assortment
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of diabetic patients restricting some to as little as 400 calories per day. He published his 
findings of 76 of the 100 patients he treated in 1919 (Total dietary regulation in the 
treatment of diabetes), some patients survived for a few years others only for a few months. 
Allen’s diets were generally thought to be the best therapy at the time and were adopted by 
medical schools and up to date practitioners.
During this time many were dying from diabetes, but Eugene Opie (an American at Johns 
Hopkins University in Baltimore) in 1901 described that in a high proportion of autopsies 
destructive changes could be seen in the pancreatic “islands of Langerhans”.
In 1908 Georg Ludwig Zuelzer a young German physician collected pancreas glands from 
animals at the height of digestion. He pressed out the juice and treated it with alcohol to 
precipitate the proteins. The material was then freed from the alcohol and injected into 
dogs. He managed to reduce the urine sugar output in these dogs with the substance he 
called “acomatrol”. He treated 8 patients and successfully reduced the amount of sugar in 
their urine. Indeed he injected acomatrol into a fifty year old diabetic in a private clinic in 
Berlin. The patient was comatose, but after receiving the extract his condition improved, 
only to deteriorate and die when supplies of Zuelzer’s acomatrol dried up (MacCracken,
1997). His extract needed purifyiiig further to decrease the side effects of vomiting, high 
fevers and convulsions that his patients were suffering. Zuelzer continued to attempt to 
make a pancreas preparation suitable for the treatment o f diabetes. He visited many 
pharmaceutical companies to try to gain backing without success. Finally in 1911 he was 
given funding by one, however he had little success and in 1914 his hospital was taken over 
by the military. The presence of digestive enzymes in the pancreatic products was causing 
great difficulties. Several others including Scott, Starling, Knowlten and Macleod continued 
research along the lines of extracting and purifying the pancreatic juices, but their work was 
also interrupted by the outbreak of World War 1.
In 1921 Banting (an orthopaedic surgeon) returned from the war, and reading an article by 
Barron written in 1920 describing the old experiment of ligating the pancreatic ducts which 
results in atrophy of the exocrine pancreas leaving the islets intact, it occurred to him that
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the troublesome digestive enzymes may be circumvented using this technique. Under 
Professor Macleod at the University of Toronto he was given the assistance of Best, a 
medical student. They started ligating ducts in the pancreas of dogs and after the pancreas 
had degenerated injected extracts of it into depancreatised dogs. They recorded a lowering 
of the urine sugar output, however they soon ran out of pancreatic tissue. At this point they 
too were confronted with the problem of preparation and refinement of the extracts of 
pancreatic tissue. Collip was then added to the group and brought to bear the experience 
gained in several years of devotion to this type of chemistry. They moved on to using the 
foetal calf pancreas to avoid the activity of trypsin, and then onto ox pancreas, with which 
they discovered that if the whole gland was immediately placed in acid aqueous alcohol 
yielded adequate amounts of insulin. The use of alcohol and acid in the extraction process 
circumvented the enzyme action. The resulting extract in concentrated form was first given 
to the investigators themselves.
In January 1922 its first use in patients was begun. Leonard Thompson a 14 year old 
weighing only 641b was the first patient to be given insulin. He received 7.5 ml in each 
buttock of “thick brown muck”. Although initially his blood sugar and glycosuria fell, 
unfortunately he developed abscesses at the injection sites and became more unwell. The 
injections were stopped. Six weeks later he was given Collip’s more refined extract, his 
blood sugar fell and he quickly began to gain weight. Collip’s extract was then given to a 
number of patients with diabetes at Toronto General hospital, they responded well. During 
the summer of 1922 insulin began being produced commercially by Eli Lilly in Indianapolis, 
USA. The first insulin complementary deoxyribonucleic acid (cDNA) was cloned and 
sequenced from rat islet messenger ribonucleic acid (mRNA) by Ullrich et al., (1977). The 
human insulin gene was later fully characterised (Bell et al., 1980). Owerbach et al., 1981, 
located the human insulin gene to the short arm of chromosome 11. Recombinant DNA 
techniques have allowed biosynthetic human insulin to be produced by Escherichia coli 
(Keefer et al., 1981).
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The Insulin molecule
Structure of the insulin molecule.
Sanger and co-workers determined the complete amino acid sequence of insulin and its 
primary structure in 1955 (Ryle et al 1955). Schlichchtkrull (1956) demonstrated that the 
rhombohedral crystals of insulin contain two zinc atoms and consisted of six molecules of 
insulin. Extensive crystallographic studies of the three dimensional model of the insulin 
molecule demonstrated that the hexamer of insulin with a molecular weight of 36000 Da (at 
neutral pH in the presence of zinc) consisted of three slightly asymmetric dimers each with a 
molecular weight of 12000Da (Adams et al 1969, Blundell et al 1972, Hodgkin, 1972) (see 
figure 1).
Figure 1 (after Hodgkin, 1972)
Schematic representation of the three dimensional structure of insulin
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The secondary structure of the monomers includes three a-helical regions (Blundell et al 
1971 & 1972), of which two exist on the A chain and one on the B chain. The folding of the 
B chain around the A chain core is also brought about with disulphide bridges between 
cysteine residues. The globular structure achieved in this way provides the molecule with a 
hydrophobic core which is essential for its structural stability, all polar residues are on the 
surface and the non polar residues, mainly on the B chain, are buried during the formation of 
the dimers and the 2 zinc-insulin hexamers. Insulin aggregation in solution depends on 
concentration, pH, ionic strength and the presence of divalent cations and anions (Blundell 
et al., 1972, Bradbury and Brown, 1977). X-ray studies demonstrate that most mammalian 
and fish insulins form similar hexamers, (except the hagfish, guinea pig and coypu (Cutfield 
et al., 1974, Peterson et al., 1974, Wood et a l, 1975).
Biosynthesis of insulin
Insulin is first synthesized as preproinsulin (molecular weight 11 500Da) on the rough 
endoplasmic reticulum (RER) in the P-cells of the islets of Langerhans in the pancreas 
(Patzelt et a l, 1978, Steiner et a l ,1974). The islets of Langerhans comprise 1-3% of the 
pancreatic mass and are probably derived from the ectoderm (Bell and Hockaday, 1996). 
The N terminus of preproinsulin has a hydrophobic extension of 23 amino acid residues 
which directs release of the nascent polypeptide chain to the cisternal space of the RER 
(Chan et a l, 1976). The signal sequence is rapidly removed by proteolytic cleavage and the 
resulting proinsulin molecule (molecular weight 9390Da and 86 amino acid residues) is 
transferred via the vesicles of the RER to the Golgi apparatus. This transfer is an energy 
dependent process (Howell and Tyhurst, 1972) and by pulse labelling technique has been 
shown to occur in about 15 minutes.
In the Golgi apparatus proinsulin is packed into clathrin coated trans-Golgi vesicles 
containing an ATP-dependent proton pump (Orci et a l, 1986 & 1984). As the vesicles 
mature, H+ ions are transported inwards, via the proton pump, causing a reduction in pH and 
thus increasing the activity of the proteolytic enzymes and ensuring the conversion of
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proinsulin to insulin within maturing vesicles. This process takes 60-90 minutes (Orci et al., 
1973)
The connecting peptide (C-peptide) is joined to the insulin molecule by basic amino acids; 
two arginines at the amino end and a lysine and arginine at the carboxyl end. These are the 
points of trypsin and carboxypeptidase B-like enzymatic cleavage which convert proinsulin 
into insulin, consequently releasing these basic residues (Orci et al, 1986, Steiner and Oyer, 
1967, Chance et al, 1968).
The conversion of proinsulin to insulin takes place in non-coated mature secretory granules 
(Orci et al., 1984) and the removal of the C-peptide chain decreases its solubility. The 
resulting insulin is crystallized with 2 zinc ions per 6 insulin molecules and is stored in 
equimolar ratio with C-peptide in secretory granules where it is available for secretion 
through exocytosis (Orci et al., 1984). A small amount of proinsulin co-crystallizes with 
insulin (Steiner, 1973) and constitutes approximately 5% of insulin secretion.
Insulin secretion is stimulated primarily by a rise in glucose concentration. Glucose is 
metabolised through the glycolytic pathway generating ATP within p-cells (Randle, 1993). 
The increase in intracellular ATP concentration (Ashcroft et al., 1984) or ATP/ADP ratio 
(Ashcroft and Ashcroft, 1990) leads to closure of the ATP sensitive potassium channels and 
depolarisation of the p-cell membrane thus causing the entry of calcium through calcium 
channels (Sussman et al., 1987). Calcium then activates Ca-calmodulin dependent protein 
kinase which in turn leads to phosphorylation of specific protein substrates and the release 
of insulin from the P cell.
The Insulin Receptor
The insulin receptor consists of a membrane spanning glycoprotein complex lodged in the 
plasma membranes of cells, with an apparent molecular weight of 450 kDa and consisting of 
two distinct glycosylated subunits (Yip et al, 1978 and 1980). There are two a-subunits and 
two p-subunits linked covalently by disulphide bonds. The two a-subunits are located at the
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extracellular face of the plasma membrane and contain the insulin binding domain. The two 
p-subunits are held together by disulphide bonds, they consist of three regions: an 
extracellular domain of 194 amino acid residues with a segment rich in cysteine residues and 
forming disulphide bridges with the a-subunits, a hydrophobic transmembrane domain of 23 
amino acid residues, and an intracellular domain of 403 amino acid residues that contains a 
catalytic site and several sites of autophosphorylation (Kasuga et al, 1982 a and b, White et 
al, 1985).
Following binding of insulin to its receptor a series of events is triggered: internalisation of 
insulin, processing of insulin and/or the insulin receptor comlex and initiation of a wide 
spectrum of metabolic processes. Experimental evidence suggests that insulin binds to its 
receptor with high affinity in a ratio of 1:1 at physiological concentrations. Carpentier et al 
(1979 a & b) using radio-iodinated (^^ I^) insulin demonstrated that the insulin receptor 
complex is internalised (endocytosis), generating coated vesicles containing the complex in 
the subplasmalemmal cytoplasm. The acidic pH within the endosomes causes dissociation 
of insulin from the receptor (Farquhar, 1983; Tyko and Maxfield, 1982). Insulin is then 
degraded within the secondary lysosomes. The internalised receptor (Fehlmann et al 1982 a 
& b; Juul et al 1986) is either recycled to the cell surface from endosomes (Marshall et al 
1981; Carpentier et al, 1986) or degraded (Heindreich et al, 1983; Berhanu et al, 1982).
Insulin affects many cellular systems including: transport of molecules across the plasma 
membrane, levels of cyclic nucleotides, activities of key enzymes in intermediaiy 
metabolism, rates of protein synthesis and degradation, rates of DNA and RNA synthesis, 
including specific gene expression and cellular growth and differentiation. However, it was 
not understood how the rapid effects of insulin (observed within seconds) could be 
explained by the process of internalisation (Lamer et al., 1981).
Kasuga et al., (1982a) found that the addition of insulin to cells led to rapid phosphorylation 
of the P-subunit on serine and threonine residues. Subsequently, the (3-subunit was shown to 
be phosphorylated on tryrosine residues in cell free systems which led to the idea of tyrosine 
kinase activity associated with the insulin receptor itself (Kasuga et al., 1982b).
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It was then shown that immediately after insulin binds to the receptor a cytoplasmic protein, 
is phosphorylated on tyrosine reidues (White et a l, 1985). This protein which is now 
referred to as insulin receptor substrate 1 (IRS-1) has been purified from rat liver by affinity 
chromatography and the cDNA of this protein has been isolated (Rosenberg et a l, 1991; Sun 
et a l, 1991). This protein has 10 tyrosine phosphorylation sites. After phosphorylation, 6 of 
these tyrosine-containing regions can interact with other proteins which have Src homology 
(SH2) domains (Koch et a l, 1991). One of the cytoplasmic proteins which has the SH2 
domain is phosphotidylinositol 3’-kinase. It has been demonstrated that 
phosphotidylinositol 3’-kinase is associated with the IRS-1 (Sun et a l, 1991). Several other 
signalling proteins containing SH2 domains eg phosphotyrosine phosphatase Syp (Kuhne et 
a l, 1993) and growth factor receptor bound-2 (grb-2) (Baltensperger et a l, 1993) have been 
shown to couple with IRS-1. This appears to connect the insulin receptor to a signalling 
chain which involves GTP-binding proteins such as ras which interact with a cascade of 
serine/threonine specific kinases (MAP-kinase cascade, mitten-activated protein 
kinase)(Gammeltoft and van Obberghen, 1986).
In vitro studies with adipocytes treated with a tyrosine phosphatase inhibitor (okadaic acid) 
demonstrated that IRS-1 was phosphorylated on serine and threonine residues, but in these 
cells the stimulation by insulin of glucose transport was inhibited (Tanti et al, 1994).
Further studies involving microinjection of anti-IRS-1 antibody into rat fibroblasts have 
suggested that IRS-1 initiates mitogenic activity of IGF-1 and insulin receptors (Rose et al, 
1994). These findings have led to the suggestion that IRS-1 has a major role in insulin 
mediated metabolic and mitogenic signalling and glucose transport.
Glucose Metabolism
Usually when the concentration of glucose is elevated (fed state) and other nutrients are 
adequate, the liver, muscle and adipose tissues are geared to anabolic process and storage. 
When dietary glucose is not available, ie in the catabolic state, glycogen stores from the liver 
and fat and protein stores are mobilized to provide an alternative energy source.
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Endogenous Glucose Production
Circulating plasma glucose, in the fed state, is mainly derived from the splanchnic bed. 
However, during a short fast, liver alone, and in a prolonged fast both liver and kidney 
(Flock et al., 1969) are geared towards glucose production. These two tissues contain 
glucose 6 phosphatase activity which catalyses the conversion of glucose 6 phosphate to 
glucose. Glucose can then be transported out of the cell by glucose transporters.
Glucose from the liver is produced by two processes: glycogenolysis and gluconeogenesis. 
Initially glycogen stores in the liver are mobilized. Studies of serial liver biopsies in human 
subjects (Nilson and Hultman, 1973) and nuclear magnetic resonance (NMR) studies to 
measure the rate of glycogen depletion from the liver (Rothman et al., 1991) have suggested 
that after an overnight fast, glycogenolysis contributes to 40-50% to the hepatic glucose 
production. After depletion of glycogen stores (20 hours of fast) gluconeogenesis maintains 
hepatic glucose output (Consoli et al., 1987). A variety of substrates are used in this 
process. In muscle, during a prolonged fast glycogen stores and protein are released as 
lactate and alanine which are then transported and used in the liver for glucose production. 
Glycerol from adipose tissue during a prolonged fast is another gluconeogenic source and 
provides 50% of the hepatic glucose output (Bortz et al, 1972 and Nurjhan et al, 1986). 
Insulin affects glucose homeostasis by inhibiting hepatic glucose output and stimulating 
glucose disposal.
Glucose Utilization
In most tissues glucose is taken up via transport systems that display saturation kinetics. 
The intracellular glucose concentration is normally lower than the extracellular glucose 
concentration, and glucose is transported down its concentration gradient by facilitative 
diffusion via glucose transporters across the cell membrane which is thought to be the rate 
limiting step (Britton, 1964) in glucose disposal.
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Glucose taken up by the cells is either stored as glycogen or lipid, oxidised to CO2 and H2O 
or converted to lactate and alanine. The Cori (lactate) and Glucose-alanine cycles account 
for 20-25% of glucose utilization (Felig, 1973).
Various factors can influence the fate of circulating glucose, including the degree of fasting, 
the availability of substrates such as free fatty acids and various endocrine factors. The 
tissues involved in glucose utilization include splanchnic tissues, muscle, brain and adipose 
tissue. Brain and muscle are the major tissues for glucose oxidation whereas splanchnic 
tissues, adipose tissues and under certain circumstances muscle are geared for storage.
Both glucose production and utilization are affected by insulin and glucagon. The 
glycolysis pathway where glucose is broken down to pyruvate and lactate is illustrated in fig
1. The steps where insulin or glucagon has an effect by causing phosphorylation or 
dephosphorylation of the enzyme has been shown.
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Figure [ 2]- The glycolysis pathway showing the effects of insulin and glucagon on the 
enzymes involved and the steps at which 2-[^H], 3-[^H] and 6-[^H]glucose lose their label. 
PEPCK (phosphoenolpymvate carboxykinase) (Umpleby and Sonksen, 1987). GLUT is 
representing glucose transporters.
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Glucose Homeostasis
The regulation of plasma glucose levels is of central importance. Tissues such as muscle 
and liver are able to metabolise substrates other than glucose, however the brain almost 
exclusively utilizes glucose as a source of energy. Some researchers have demonstrated that 
the brain is able to metabolise ketones and lactate (Veneman et al, 1994, Maran et al, 1994, 
Amiel et al, 1991). The brain has high energy requirements estimated at approximately 
Img/kg/min glucose corresponding to about lOOg glucose per 24 hours, however it has low 
energy reserves (enough for only a few minutes), and is unable to synthesize glucose (Bolli,
1998). The energy utilised is required to maintain the ionic gradient across nerve 
membranes critical for maintenance of brain activity, and as a result of brainstem functions 
critical in maintaining life. The brain is therefore mainly dependent on the maintenance of 
a constant supply of glucose from the blood.
Intricate mechanisms to protect the supply of glucose to the brain have therefore evolved. 
Only the liver and the kidney are able to release glucose. These organs contain glucose-6 - 
phosphatase which liberates glucose into the bloodstream (Bolli and Fanelli, 1999). The 
liver and the kidney do not contribute equally to postabsorptive glucose homeostasis. It is 
generally believed that the liver makes the major quantitative contribution during this state, 
whereas the kidney has a minor role, except during prolonged starvation, when it is 
estimated that the kidney may contribute almost half of glucose production (Bolli 1998, 
Cahill et al,1966,Cahill 1970).
In normal subjects the plasma (extracellular) glucose concentration remains between 3.5 and 
7 mmol/1 despite intermittent glucose loads entering the body from the gastrointestinal tract 
following meals. The renal tubule absorbs all glucose from the glomerular filtrate up to 
concentrations of around lOmmol/1, so that in the non-diabetic individual with a normal 
renal threshold, urine is glucose free. Blood glucose is sensed in the brain (Frohman and 
Nagai, 1976, Ritter et al, 1981, Borg et al, 1995), pancreas (Taborsky et al, 1998) and liver 
(Connolly et al, 1996), each of these organs is involved in the counter-regulation response to 
low blood glucose in healthy subjects.
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The release of insulin, glucagon, growth hormone, catecholamines, glucocorticoids and 
insulin like growth-factor 1 (IGF-1) have all been shown to be sensitive to changes in 
glucose concentration (Garber et ah, 1976, DeFronzo et ah, 1977, Cryer, 1991, Bolli and 
Fanelli, 1999).
Both insulin (secreted from the (3-cells of the pancreas) and glucagon (secreted from the a  
cells) play an important role in the regulation of glucose homeostasis. A fall in blood sugar ' 
concentration that may occur in the postabsorptive state leads initially to a reduction in 
insulin secretion, by direct action of glucose on p-cells of the islets of Langerhans (Cryer 
1997, Bolli, 1998). This leads to a reduction in the plasma insulin concentration in the 
portal circulation, and therefore a reduction in the suppression of hepatic glucose output (or 
a rise in hepatic glucose output). If the blood glucose continues to drop counter-regulatory 
hormones are stimulated and released, oc-cells of the islets of Langehans in the pancreas are 
stimulated to release glucagon, this is reversed in hyperglycaemia (Matschinksy and 
Bedoya, 1989). Like insulin, glucagon is also released into the portal circulation, it has no 
effect on peripheral glucose uptake, but increases hepatic glucose production. The increase 
in hepatic glucose output is early and sustained probably because of the sustained 
stimulation of hepatic gluconeogenesis, the main mechanism of increased hepatic glucose 
output. The kidney does not appear to be affected by glucagon stimulation.
However, hyperglycaemia per se (with suppression of insulin and glucagons secretion) has 
an inhibitory effect on hepatic glucose production in man (Liljenquist et al., 1979). In 
addition, during hypoglycaemia induced by insulin in humans, Bolli et al (1985) found that 
when glucose concentrations decreased below 2.5mmol/l there was a residual hepatic 
glucose output independent of neurohormonal influences or an autoregulatory process by the 
liver. In dogs also, it has been shown that this residual hepatic glucose output is maintained 
by glycogenolysis and gluconeogenesis after a prolonged hypoglycaemia induced by insulin 
infusion (Tyler Frizzell et al., 1988).
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ACTH is released from the pituitary and stimulates a rise in cortisol several hours after 
hypoglycaemia. Short term infusion of cortisol (the main glucocorticoid in man) affects 
glucose homeostasis by increasing hepatic glucose output and decreasing peripheral glucose 
disposal (Rizza et al, 1982). However studies of patients with Cushing’s syndrome (ie with 
long term effects of excess glucocorticoids) using an intravenous bolus of D-[3-^H] glucose 
have shown that the hyperglycaemia sometimes found in these patients is primarily due to 
decreased glucose disposal rather than increased glucose production (Bowes et al., 1991). 
Furthermore, both basal (Bowes et al., 1991) and glucose stimulated insulin secretion 
(Kitabchi et al., 1973) are increased in the presence of excess glucocorticoids. In contrast, in 
the absence of glucocorticoids, insulin secretion is suppressed, for example following 
adrenalectomy in man, although the absence of the catecholamines (adrenaline and 
noradrenaline) may contribute to the effect of this example (Lenzen and Bailey 1984; 
Marker et al., 1991).
Adrenaline is released from the adrenal medulla as a result of stimulation of the sympathetic 
nervous system (Bolli and Fanelli, 1999). Catecholamines exhibit multiorgan effects. 
Adrenaline reduces secretion of insulin from the pancreas, lowering portal plasma insulin 
concentration further, and thus reducing the suppression of hepatic glucose output. It also 
increases hepatic and renal glucose output, probably secondary to increased 
gluconeogenesis. Adrenaline reduces peripheral glucose uptake and stimulates lipolysis. 
The stimulation of lipolysis contributes to counter regulation via non esterified fatty acids 
which stimulate hepatic gluconeogenesis and suppress glucose oxidation and use. The effect 
of free fatty acids on the production of glucose is greater than that on the use of glucose. 
Noradrenaline concentration in plasma rises less, but it acts though the same pathways as 
adrenaline with similar effects. It also inhibits insulin secretion and stimulates glucagon 
synthesis.
Growth hormone is released from the pituitary as a result of hypoglycaemia, it also increases 
hepatic glucose output and suppresses peripheral glucose uptake. It stimulates lipolysis and 
therefore increases plasma concentration of non esterified fatty acids and glycerol.
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Hepatic autoregulation occurs when hypoglycaemia is severe. Investigators have 
demonstrated that endogenous glucose production increases despite complete neurohumoral 
counter regulatory blockade. (As reviewed by Bolli 1998 and Bolli & Fanelli 1999).
A large part o f the counter regulation hormones’ effect, at least the ones that possess 
peripheral effects are mediated by the common pathway of increased lipolysis and greater 
plasma levels of free fatty acids. As described above these fatty acids exert their counter 
regulatory effect mainly at the liver. Thus all counter regulatory responses to 
hypoglycaemia increase hepatic glucose output either directly alone or in combination with 
an indirect effect by the stimulation of lipolysis, some also decrease peripheral glucose 
uptake. In normal physiology these defence mechanisms are appropriate as insulin is 
released into the portal circulation and has its first effects at the liver, and the liver plays a 
vital role in the production of glucose to support brain metabolism.
In insulin dependent diabetes no insulin is released by the pancreas in most cases exogenous 
insulin is administered by subcutaneously delivery, it circulates peripherally first, and is 
controlled by its pharmacokinetics, with peak actions occurring 1 to 8  hours after injection 
(Bolli, 1998). The insulin profile does not resemble physiological insulin profiles of a 
normal 24 hour day, and is unable to respond to changing insulin need (Amiel, 1998, Cryer, 
2003). In this situation the liver is relatively underinsulinised and peripheral tissue over 
insulinised. In the event of hypoglycaemia, the first line of counter regulation (that is a 
decrease in insulin release) is not possible, insulin levels remain inappropriately high 
suppressing hepatic glucose output, increasing peripheral glucose uptake and inhibiting 
lipolysis. Further counter regulation has evolved to exert itself primarily at the liver, 
suppression of hepatic glucose output is thus easily overcome since in these circumstances 
the liver is relatively underinsulinsed, however the peripheral over insulinisation presents a 
more difficult obstacle, and therefore it could be argued that greater counter regulation has 
to occur to prevent a further fall in plasma glucose and maintain the brain’s glucose supply. 
This may cause later hyperglycaemia as a result of the sustained release of counter 
regulatory hormones and their prolonged duration of action may be a factor in the overall 
deterioration in glycaemic control seen in patients with frequent hypoglycaemia. Some have
31
proposed that intraperitoneal insulin would be a more physiological replacement (see hepatic 
insulinisation page 36)
Fat and Lipid metabolism
Lipids in the plasma exist as free cholesterol, cholesterol ester, triglycerides (glycerol and 
fatty acids) and phospholipids (triglycerides and a phosphate derived group).
Plasma lipids are transported as lipid protein complexes. These lipoproteins are classified as 
chylomicrons, very low density lipoproteins (VLDL), intermediate density lipoproteins 
(IDL), low density lipoproteins (LDL) and high density lipoprotein (HDL) according to their 
densities. Insulin stimulates fatty acid synthesis from pyruvate and lactate (Denton et al., 
1975) by increasing the activity of acetyl CoA carboxylase and pyruvate dehydrogenase and 
increases the estérification of fatty-acyl CoA and glycerol to form triglycerides. Acetyl CoA 
carboxylase is inactivated by reversible phosphorylation which is catalysed by the enzyme 
cyclic adenosinemono-phosphate (cAMP) dependent protein kinase. Hormones that 
decrease the concentration of cAMP (for example insulin) will activate the enzyme whereas 
those that elevate the concentration of cAMP (for example adrenaline or glucagon) will 
cause the inactivation of acetyl CoA carboxylase (Brownsey and Denton, 1982; Holland et 
al., 1985).
Insulin also inhibits lipolysis (Garratt et al., 1979) in adipose tissue by dephosphorylation of 
the enzyme triacylglycerol lipase to an inactive form via lowering cAMP concentrations 
hence decreasing the activity of the protein kinase. The activity of lipoprotein lipase which 
hydrolyses chylomicrons and other lipoproteins to fatty acids and glycerol is increased by 
insulin in a dose dependent manner. The increase in activity is caused by cleaving the 
enzyme from the cell membrane via stimulation of a phosphatidylinositol-specific 
phospholipase C (Chan et al., 1998).
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When the concentrations of fatty acids and ketone bodies are elevated as during starvation or 
exercise there is an increased rate of their oxidation. This reduces glucose oxidation and 
utilization and increases the flux through gluconeogenesis (Randle et al., 1963). In contrast, 
in the presence of an elevated glucose concentration lipid oxidation is suppressed due to 
inhibition of lipolysis and increased fatty acid re-esteriflcation (Sugden et al., 1989).
The Endothelial Barrier
The capillaries are the sites of exchange of substances between flowing blood, extracellular 
fluid and tissue cells. The endothelial barrier provides a membrane across which substances 
move both actively and passively in response to pressure and concentration gradients. For 
small molecules (for example water, gases and small ions) equilibration is rapid (Hill 1928) 
but for macromolecules (for example yglobulins, albumin and probably insulin)the process 
is slower (Renkin, 1964). In general, there are two continuous layers in the walls of the 
capillaries: the endothelium and its underlying basement membrane or basal lamina. The 
permeability of the capillaries is dependent on the porosity of these layers.
Endothelial cells of some capillaries have been shown to have a large proportion of small 
vesicles and fenestrae (Wissig and Charonis, 1984). Vesicles have been shown to shuttle 
fluid across endothelial cells (Palade, 1961). Fenestrae are openings throughout the 
endothelial plasma membrane with a range of pore diameters around 30-80nm closed by a 
delicate unilaminar diaphragm 2-4nm thick with a nodal swelling 15nm in diameter at its 
centre (Clementi and Palade, 1969).
Endothélia of different types of capillaries differ in their permeability (Renkin 1964). The 
tightest capillaries are those of the central nervous system, retina, iris, and larger peripheral 
nerves. The endothelial cells of these capillaries have tight junctions, lack fenestrae and 
have minimal vesicle activity (Kamovsky et al 1967). Capillaries of muscle and skin have 
small openings in the junctions between endothelial cells or nonrestrictive gaps between 
cells.
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A bidirectional shuttle of pinocytic vesicles has been described for transport of 
macromolecules across their walls independent of fluid volume movement (Garlick and 
Renkin, 1970, and Renkin 1979). Data from studies with various sized dextrans, 
polyvinylpyrrolidone and proteins ranging from l - 1 2 nm radius from skeletal muscle 
demonstrated that solutes measuring 4-12nm in radius drained from lymphatics and did not 
easily cross through the capillary wall (reviewed by Parker et al 1984). Wissig, 1979 and 
Williams and Wissig, 1975 showed after intravenous injection of a variety of molecules with 
peroxidase activity (size range 1900-40000 Da or molecular diameter 2-5nm) that the 
smaller molecules leave the capillary lumen more rapidly and reach a higher concentration 
in the pericapillary interstitium of the diaphragm muscle than do larger molecules. It was 
shown that ferritin (an electron dense protein probe) with Mr 750 000 Da and molecular 
diameter lln m  was unable to leave the capillary lumen (Bums and Palade, 1968b). The 
behaviour of these molecules in the size range 1,900-750 OOODa suggests that they use a 
different diffusion pathway with some restrictions to enter the interstitium. Two structures 
have been proposed to serve this pathway, 1 , the transendothelial vesicular channels and 2 , 
the cleft between endothelial cells (Wissig and Williams, 1975).
The most permeable capillaries are found in the liver. In the liver, sinusoids are lined by 
highly fenestrated epithelial cells, between which there are large gaps. The sinusoids also 
have no basal lamina (Wisse 1970). Because of the large gaps in the endothelial cell layer 
and the absence of a continuous basal lamina, no significant barrier exists between blood 
plasma in the sinusoid and the hepatocyte plasma membrane (Ross et al, 2003). This is 
known as the “space of Disse” (the perisinusoidal space)(Gray, 1973, Reichen, 1999). 
Measurement of circulating chylomicrons in the space of Disse in the rat liver revealed a 
substantial filtration effect of endothelial fenestrations only on chylomicrons greater than 
250nm in diameter (Naito and Wisse, 1978).
Early infusion studies with pork proinsulin in dogs (Tomkins et al 1981) and 
hyperinsulinaemic-euglycaemic clamp studies with human proinsulin in healthy volunteers 
(Revers et al, 1984, Glauber et al, 1986, Galloway et al 1992) suggested that proinsulin was
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more active in the liver (glucose Ra) than in the periphery compared to (glucose Rd) insulin. 
The reasons for the differential effect of proinsulin on glucose Ra and Rd could be attributed 
to differences in local distribution or metabolism, to differences in binding or activation of 
the receptors or to differences in the post-receptor cascade. Although proinsulin had 8-9% 
biopotency of that of insulin, the postreceptor activities of insulin and proinsulin were 
shown to be the same in cultured rat hepatocytes (Agius et al, 1986). Furthermore, Ciraldi et 
al (1986) showed that glucose transport was affected similarly for insulin and proinsulin in 
rat adipocytes in vitro.
The in vitro results suggested that differential observations on glucose Ra and glucose Rd 
from the in vivo studies could simply be due to the differences in distribution of proinsulin 
in the liver compared to the periphery in comparison to insulin. The observation that 
proinsulin exhibited apparent hepatoselectivity promoted the suggestion that the mechanism 
of this differential effect could relate to the effect of the increased molecular size (proinsulin 
9390 Da versus an insulin 5807 Da) on the rate of passage through the capillary walls and 
hence to insulin receptors in intact tissues. Low receptor affinity per se does not convey 
relative hepatoselectivity (Chap et al, 1987) In support of the hypothesis for the existence of 
a capillary endothelial barrier is the observation that monomeric insulin analogues (eg B25 
Asp, B9 Asp and B27Glu)(Brange et al, 1988, Kang et al, 1991) are absorbed more rapidly 
from subcutaneous tissue in the reverse direction through the capillary endothelial barrier 
than native insulin which at concentrations used for treatment subcutaneously are mostly 
dimeric and hexameric. Hyperinsulinaemic euglycaemic clamp studies performed in pigs 
demonstrated that monomeric insulin analogues (BIO Asp and B9Asp and B27 Glu) were 
equipotent in stimulating glucose Rd and inhibiting glucose Ra in comparison to human 
insulin (Ribel et al, 1990).
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Figure 3. Schematic representation of albumin binding of insulin detemir, and potential 
mechanism for differences in effect on the liver and periphery.
Hepatic insulinisation
In normal physiology the pancreas releases its hormones into the hepatic vein these 
hormones must pass the liver before reaching the systemic circulation (Figure 4.). 40-60% 
of the insulin presented to the liver is removed in a single passage (Field et al 1973, Ishida et 
al 1983, Chap et al 1987). Flepatic extraction of insulin is therefore potentially important for 
control of the circulating concentration of the hormone. Using insulin pharmacologically in 
the treatment of Type 1 diabetes, insulin is administered subcutaneously and absorbed 
directly into the systemic circulation (Figure 5). In the absence of the portal-peripheral 
gradient, glycaemic control is only achieved by relative portal-peripheral hyperinsulinaemia. 
Many factors will influence hepatic exposure to subcutaneously delivered insulin including, 
rate of absorption from the injection site into the venous system, the volume of distribution, 
possible insulin extraction in the pulmonary and mesenteric capillary beds before reaching
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Figure 4. Schematic Representation of Physiological Insulin Production.
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the hepatic portal vein and the blood flow in the hepatic artery. However, concentration of 
insulin after intraportal administration is affected only by portal vein flow (from the gut).
The effects of insulin on glucose and fat metabolism are not fully understood. Hormonal 
control of glucose metabolism may be either direct by inhibition of glycogenolysis and or 
gluconeogenesis in the liver (Hers and Ave, 1983; Chiasson et al 1976), or indirect by 
restriction of flux of gluconeogenic substrates or rate of lipolysis from peripheral tissues, 
(Giaccaetal, 1992).
Many studies have shown the importance of intraportal delivery of insulin. Intraportal 
delivery of insulin to the liver has been shown to have an important role in the regulation of 
hepatic glucose output in normal and diabetic dogs (Stevenson et al 1978, 1981 and 1983)). 
Ishida et al (1984) demonstrated that in depancreatized diabetic dogs the liver is more 
sensitive than peripheral tissue to small changes (a rise from less than 2|uU/ml to 9 and 16 
pU/ml) in the plasma insulin concentration. Griffen et al (1987) performed a study 
catheterising either the jugular vein or the portal vein (ie systemic versus portal insulin 
delivery) in diabetic rats. They demonstrated that insulin exerts its metabolic and mitogenic 
effects by direct action on the liver and established that the insulin delivery via the portal 
vein is important for glucose homeostasis. Spangler, 1985 and Spangler et al, 1986) 
demonstated that peripherally delivered vesicle encapsulated insulin preparations (VEI) and 
insulin had an equivalent capacity to suppress hepatic glucose output but VEI was less 
effective in stimulating glucose disposal.
Whilst these studies suggest that intraportal delivery of insulin is important in the control of 
glucose Ra other data have suggested that systemic delivery of insulin may be more 
effective in the suppression of glucose Ra. Glucose turnover studies with hyperinsulinaemic 
euglycaemic clamping, in depancreatised dogs (Giacci et al 1992) or in normal dogs 
combined with an infusion of somatostatin (Ader and Bergman 1990) demonstrated that 
systemic delivery of insulin was more effective in the suppression of hepatic glucose output 
than portal delivery.
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In kidney pancreas transplanted patients, the surgical anastomoses are such that hormones 
released from the transplanted pancreas drain into the systemic circulation. This surgical 
method abolishes the normal portal-peripheral insulin gradient and also results in relative 
hyperinsulinaemia in the periphery. Data from metabolic studies in patients with such 
transplants compared to a control group using infusion of D[6 -^H] glucose and 
bicarbonate and a meal enriched with D-[2-^H] glucose, suggest that systemic delivery of 
insulin normalised the basal glucose concentrations to a similar extent as the control group 
and there was a tendency for a more effective suppression of hepatic glucose Ra than in the 
control group (Katz et al 1991).
Other studies find portal and systemic delivery of insulin to be equally effective in the 
suppression of glucose Ra. A comparative study of glucose turnover performed in diabetic 
rats which had received transplanted islets either under the kidney capsule (peripheral 
delivery) or in the splenic pulp (portal delivery) (Kruszynska et al, 1985) indicated that 
glucose turnover and recycling were not different between the groups. In another study the 
direct and indirect action of insulin on carbohydrate metabolism during fasting and after an 
oral glucose load has been investigated in a group of dogs in which the portal vein was 
anastomosed to the inferior vena cava (peripheral delivery) (Kryshak et al 1990). This 
resulted in insulin sectreted by the intact pancreas passing directly into the systemic 
circulation, bypassing extraction by the liver and thereby producing hyperinsulinaemia in 
the periphery. Glucose Ra and Rd, measured with D-[2-^H]glucose and D-[3-^H]glucose, 
after a meal ingestion in these dogs, was not different from a control group suggesting that 
glucose Ra may be controlled by a peripheral signal.
Cherrington in his review “control of glucose uptake and release by the liver in vivo” 
(1997), discusses glucose homeostasis when fasting, as well as the effects of glucoregulatory 
feedback loops in the regulation of hepatic glucose output. In particular the direct and 
indirect role of insulin on hepatic glucose output is discussed. Evidence for indirect 
mechanisms of insulin action on hepatic glucose output demonstrated by Bergman and 
Giacca are presented as well as further studies by the author. Cherrington concludes that
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“insulin thus appears to acutely inhibit liver glucose output through a direct effect on 
glycogenolysis and an indirect effect on glycolysis/gluconeogenesis. When one considers 
that the sinusoidal insulin level in a normal individual is 2-2.5 times the arterial insulin level 
and that the liver is extremely sensitive to alterations in the portal insulin concentration, it 
becomes evident that changes in insulin secretion must bring about the majority of their 
effects via a direct action on the liver. It is also obvious, however, that when insulin is 
administered peripherally, such as occurs in insulin-requiring diabetic individuals, the 
indirect effects of the hormone on the liver will take on greater significance.”
One explanation for the conflicting conclusions of the experiments described in this section 
could be the choice of mathematical model used for calculation of glucose Ra and Rd. The 
results from most of these studies were calculated using Steele’s model (a non-physiological 
mono-compartment model; Steele, 1959 and Steele et al, 1965) which has been shown to 
underestimate glucose Ra and may introduce errors in the conclusions reached. More 
experiments and better mathematical models of glucose kinetics are required to establish the 
effects of insulin on glucose metabolism.
Long Acting insulin
Background
Initially insulin treatment consisted of subcutaneous injections of insulin shortly before 
meals. In order to avoid multiple injections a number of attempts were made to prolong the 
duration of action of insulin or to slow its absorption. Substances used were gum arabic 
(1923), lecithin (1923) and oil suspensions (1925) (Rosskamp and Park 1999). These 
attempts were mostly unsuccessful because of poor stability or side effects at the local 
injection site.
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The first successful insulin preparation with a prolonged action was protamine insulin 
(Hagedom et al 1936). Here the principle of protracting the insulin action was to make the 
insulin less soluble at the neutral pH of tissue fluid. When injected as a suspension, the 
duration of action was roughly twice as long as that of regular unmodified insulin. 
Protamine insulin is a complex of the fish protein protamine and insulin. When injected 
subcutaneously proteolytic enzymes degrade the protamine and the insulin is absorbed. A 
further way of protracting the action of insulin was the so-called lente series. These were 
preformed amorphous or crystalline suspensions obtained by addition of small amounts of 
zinc ions (Hallas-Moller 1956). Since their introduction in the 50s the technology of 
prolonging insulin action has remained relatively unchanged, until now.
In the 1990s the link between metabolic control and development of micro vascular 
complications became firmly established (DCCT). This has led to a renewed interest in 
long-acting insulins on the basis of a new therapeutic concept. Now the objective is not 
avoidance of multiple injections but the imitation of the physiological secretion of basal 
insulin in healthy subjects, with additional mealtime insulin requirements taken care of by 
short acting insulin bolus injections before meals. This basal-bolus concept is the 
cornerstone of any kind of intensified insulin treatment, which leads to significantly better 
metabolic control than one or two insulin injections per day can provide (Rosskamp and 
Park 1999). However this therapy is not without its problems, currently available long 
acting insulins were recognised not to be good at imitating physiological secretion of basal 
insulin. They had peaks of action, and they were variable in absorption (Barnett, 2003). 
Therefore renewed interest in prolonging the duration of action of insulin led to 
developments along different strategic routes.
It was hoped that proinsulin would increase basal insulin concentrations, but concerns on 
cardiovascular safety that arose from clinical studies meant this work was abandoned 
(Owens et al, 2001). Proinsulin’s metabolite, des (64,65)-human proinsulin had an even 
shorter period of action than NPH insulin and was discontinued (Owens et al, 2001). 
Slowing absorption and clearance by strengthening hexameric interactions in the form of 
cobalt (Ill)-insulin complex also proved unsuccessful (Burge and Schadel, 1997). However,
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increase of the isoelectric point of insulin from 5.4 towards neutrality thereby causing 
precipitation or crystallisation at the site of injection, delays absorption, and prolongs the 
effect of insulin (Markussen et al, 1990). The first acid soluble extended action insulin 
analogue made by this method was Novosol Basal (GlyA21, ArgB27, ThrBSO-NHz-insulin) 
(Jorgenssen et al, 1989), but escalating dose requirements (reduced bioavailability) possibly 
associated with local inflammatory reactions at the site of injection, meant that this insulin 
was also abandoned.
On the basis of the same concept, a di-arginylinsulin analogue known as insulin glargine 
was developed that had a much slower and more reproducible rate of subcutaneous 
absorption than NPH insulin (Owens and Barnett, 2000), resulting in slower onset and 
extended effect. An additional phenol molecule bound to the hexamer of crystalline insulin 
glargine might further contribute to its protracted action. Plasma glucose and insulin 
concentrations vary less between patients when insulin glargine is used compared to 
ultralente insulin (Lepore et al, 2000, Heineman et al, 2000).
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Insulin detemir
Physical and chemical properties
Insulin detemir is produced by a process including recombinant DNA technology using 
Saccharomyces cerivisiae and chemical synthesis. The molecular formula is C267H402N 6 4S6 
and the molecular weight is 5916.9 Da. In comparison to human insulin, the amino acid 
residue at position B30 has been omitted, and a 14-C fatty acid chain has been attached to 
position B29. The molecule is lipophilic due to the fatty acid chain. By adding zinc to the 
formulation, the molecule is stabilized and hexamers are formed making it hydrophilic and 
thereby soluble in water (Kurtzhals et al, 1995, Markussen et al, 1996).
Figure 6 .
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Pharmacology
Like native insulin, insulin detemir exists predominantly as hexamers in the prescence of 
zinc and phenol. The fatty acid side-chains contribute to the aggregation of hexamers.
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which results in delay in dissociation into monomers, and thereby may delay systemic 
absorption (Havelund et al, 2004, Brunner et al, 2000), In monomeric state, the 14-C fatty 
acid chain attached to position B29 binds to the fatty acid binding sites of albumin in the 
subcutis, which further delays absorption into the bloodstream (Havelund et al, 2004, 
Brunner et al, 2000).
Figure 7.
Structure of the insulin detemir dimer
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Figure 8.
Di-hexamerisation of insulin detemir
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Formulation
There have been three formulations of insulin detemir used during its clinical development 
program. Formulation A was the first and contained 600 nmol/ml insulin detemir, and 
glycerol as an isotonic agent. One dosing unit was defined as 6  nmol, the same as in current 
human insulin products. Formulation B contained 1200 nmol/ml insulin detemir and had 
mannitol as isotonic agent. One dosing unit was defined as 12 nmol. The final formulation 
of insulin detemir formulation C contains 2400 nmol/ml, one dosing unit being defined as 24 
nmol.
The constituents in formulations B and C are insulin detemir, phenol, m-Cresol, mannitol, 
disodium phosphate, sodium chloride, zinc (as zinc acetate), hydrochloric acid and water for 
injections. Both formulations are clear and colourless and are at pH 7.4. In this study we 
have used formulation B. (Investigator’s Brochure, Soluble, basal insulin analogue Insulin 
Detemir (NN304))
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Efficacy pharmacology
The receptor binding properties of insulin detemir have been studied using soluble human 
insulin receptors and the human hepatoma cell line HepG2. The affinity of insulin detemir 
for the insulin receptor was about 18-46% relative to human insulin using soluble receptors, 
(Markussen et al, 1996 and Kurtzalls et al, 2000) and 27% (when corrected for albumin 
binding) using HepG2 cells. Correction for albumin binding is necessary to get a measure 
for the receptor affinity, when assay buffers containing albumin are used, as only free (non­
albumin bound) insulin detemir is available for binding to the receptor.
Insulin binding/dissociation kinetics were studied using Chinese Hamster ovary cells over 
expressing the insulin receptor (CHO-hIR cells). Insulin detemir dissociates about 2 times 
faster from the insulin receptor than human insulin (Kurtzhals et al, 2000).
Activation of the insulin receptor tyrosine kinase (IRTK), was studied using CHO-hIR cells. 
Insulin detemir was approximately 9.5% as potent as human insulin in stimulating IRTK 
activity (corrected for albumin binding) (Kurtzhals et al, 2000).
The IGF-1 receptor binding properties of insulin detemir were examined using soluble 
human IGF-1 receptors, and using HepG2 cells. The affinity of insulin detemir for the IGF- 
1 receptor was determined to 16% relative to human insulin using soluble receptors and to 
41% (corrected for albumin binding) using HepG2 cells (Kurtzhals et al, 2000).
Pharmacokinetics and protein binding
The albumin binding properties of insulin detemir have been extensively studied using an 
immobilised human serum albumin preparation (Kurtzalls et al, 1995 & 1997). The binding 
constant of insulin detemir for HAS was determined to be 2.4 x 10-5 M-1 at 23 *^C and 1.0 x 
10-5 at 37®C in this assay system. Based on this binding constant, insulin detemir is 
estimated to be 98.4 % albumin bound in plasma (37°C, 0.6mM albumin). This estimate is
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consistent with in vitro studies using ^^^I-labelled insulin detemir in human plasma which 
determined the plasma protein binding (98.8%) of insulin detemir.
The interaction between albumin binding of insulin detemir, fatty acids and selected drug 
substances including warfarin, acetylsalicylic acid, diazepam, phenylbutazone, valproic acid, 
ibuprofen, tolbutamide and glibenclamide was also examined in vitro using the immobilised 
human serum albumin preparation (Kurtzalls et al, 1997). Insulin detemir binds to the fatty 
acid binding sites of the albumin molecule. The binding of insulin detemir to the 
immobilised human serum albumin preparation was independent of the binding of drugs in 
the two major binding pockets located in domains HA and IIIA of the albumin molecule. 
None of the tested drugs competed with the albumin binding of insulin detemir at clinically 
relevant drug to albumin concentration ratios. In conclusion the in vitro studies do not 
suggest any clinically relevant albumin binding interactions.
Figure 9.
Distinct binding sites on albumin
Nfvr2
Curry S et al. Nature Structural Biology 1998:5:827-835
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Mitogenicity
The biological effects of insulin are both metabolic and mitogenic. The metabolic potency 
was evaluated by measuring stimulation of lipogenesis in primary mouse adipocytes. 
Insulin detemir stimulated lipogenesis with a potency of approximately 29% of human 
insulin (corrected for albumin binding) (Kurtzalls et al, 2000). This is consistent with the 
relative affinity to the insulin receptor.
The mitogenic potency of insulin detemir was evaluated using Chinese Hamster ovary cells, 
K1 strain (CHO-Kl), human mammary cancer fibroblasts (MCF-7 cells) and human 
osteosarcoma cells BIO (Saos/BlO cells), respectively. The mitogenic potency of insulin 
detemir was determinined to be approximately 9% (CHO-Kl), 14.6% (MCF-7) and 11% 
(Saos/BlO) relative to human insulin after correction for albumin binding (Kurtzhals et al, 
2000).
Taken together the in vitro pharmacology studies indicate that insulin detemir is less potent 
than human insulin in binding to insulin and IGF-1 receptors and in stimulating metabolic 
and mitogenic responses.
Aims of this study
To determine whether insulin detemir by the nature of being a larger protein bound insulin 
molecule has different effect on glucose and lipid metabolism when compared to NPH 
insulin.
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Chapter 2
Clinical methodology
Introduction to the glucose clamp technique
A particular problem encountered in studies investigating glucose metabolism is the 
interrelationship between glucose concentration and insulin. Initial attempts were made to 
make comparisons during a standard glucose tolerance test but both insulin and glucose 
concentrations are in a state of flux, thus rendering it difficult to separate cause and effect. The 
feedback loop between glucose and insulin is broken by controlling blood glucose 
concentration by frequent measurement and altering an exogenous glucose infusion. Two 
types of clamp can be performed:
i. Hyperglycaemic clamp in which blood glucose is held at hyperglycaemic levels and the 
insulin response measured.
ii. Hyperinsulinaemic euglycaemic clamp in which an insulin infusion is given and blood 
glucose is maintained with an exogenous infusion of glucose.
These two methods measure beta cell responsiveness and insulin action respectively. The latter 
was used in the studies reported here to compare the actions of insulin detemir and NPH.
Isotope dilution
The tracer dilution technique was introduced by Stetton et al in 1951 for measuring glucose 
turnover using a constant infusion of labelled glucose. Later, administration of a priming 
injection of labelled glucose followed immediately by a constant infusion of the labelled 
glucose was found to shorten the time required for mixing the labelled glucose in the body
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glucose pool (Steel et al., 1956; Searle et al., 1954). Constant isotope infusions were also 
used to measure the glucose appearance rate in non-steady state conditions during 
hyperinsulinaemia (Steele et al., 1956). The tracer dilution technique in combination with a 
constant insulin infusion and a euglycaemic clamp was used by Steele et al. (1965). This 
method provided a means for the assessment of the differential effects of insulin on glucose 
metabolism in the absence of any fluctuations in the concentration of glucose or counter- 
regulatory hormones. Using these techniques in most circumstances the endogenous rate of 
glucose appearance (Ra) equals the hepatic glucose production rate as apart from a small 
contribution by the kidney, the liver is the only organ responsible for de novo glucose 
production (Dmry et al\95V).
There are potential inaccuracies in these methods. For example during hyperinsulinaemic 
euglycaemic clamps many workers have reported negative values for hepatic glucose 
production, which is clearly impossible (Defronzo et al 1985, Butler et aï 1990, Ward et al 
1990). Everyone has assumed when negative values are reached that hepatic glucose output is 
zero but this calls into question the methodology used. The source of the errors in such studies 
has stimulated much discussion and investigation. Potential sources of error include:
a) Inability of the simple model to cope with the complex in-vivo physiology of glucose 
metabolism. The Steele model is a simple one compartment model with a fixed pool volume 
which does not mirror the complex multicompartment physiology of glucose metabolism. 
More sophisticated models have been proposed. However the original Steele model is still 
used widely as it is easily understood and suited to individual clinical studies (Insel et al 1975, 
Radzuik et al 1974, Steele et al 1974). The errors generated are proportional to the rate of 
change of tracer enrichment and this can be offset by “spiking” the exogenous glucose infusion 
with tracer to ensure uniform plasma enrichment during the study (Finegood et al 1987).
b) Tracer recycling. The isotope dilution technique assumes that once labelled tracer 
has entered a metabolic pathway it does not return to the pool in its original molecular form. If 
a tracer does return to the pool it is “recycling”. Different tracers lose their labels at different 
positions in their metabolic pathways (Wolf 1984) and it is therefore possible for recycling to
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occur leading to erroneous estimates for Ra and Rd (Bell et al 1986). For example glucose 
enters the glycolytic pathway and is broken down to lactate, pyruvate or alanine which can be 
converted back to glucose in the Cori cycle. This has been estimated to account for up to 20% 
of the hepatic glucose production (Reichard et al 1963). Thus glucose labelled with deuterium 
or tritium on carbon atoms 2, 3 or 6  are now the most commonly used tracers (See Figure 2 for 
the steps at which labels are lost). [6 ,6 -^H2] glucose was used in the studies below. It loses one 
of its labels in the pyruvate carboxylase step and one between malate and lumarate.
c)Isotope discrimination and tracer impurities. An assumption is made that the isotope 
tracer is metabolised in an identical manner to unlabelled tracer. There is evidence in vitro to 
suggest that some isotopes are metabolised in different ways (Argoud et al 1987). Finegood et 
al (1988) have suggested that different arterio-venous specific activity of [ tf]  glucose 
suggested differential metabolism but others have shown that impurities in the tracer which are 
metabolised several fold more slowly may have accounted for the reported a-v differences 
(Butler et al 1990, Schwenk et al 1990). Thus highly purified tracers are essential for accurate 
metabolic studies. In comparison to radioactively labelled glucose the stable isotope labelled 
glucose is theoretically less likely to be subject to isotope discrimination as there is less of a 
mass difference between it and the native glucose (Wolfe 1984).
Calculations
Rate of appearance (Ra), and Rate of disappearance (Rd) were calculated using the model 
originally proposed by Steele (1959) and adapted by Finegood et al (1987) to account for the 
addition of stable labelled tracer to the exogenous glucose infusate.
51
where Ey is the enrichment of the basal continuous [6 ,6 -^H2] glucose infusion in APE, Ep(t) and 
Evar are the APE of the plasma and enriched glucose infusate respectively, ly is the continuous 
tracer infusion rate (mg/kg/min, p is the pool fraction (ratio of effective glucose to actual space) 
which was assumed to be 0.65, V is the glucose space assumed to be 220ml/kg of the body 
weight, G(t) is the plasma glucose and Ivar is the exogenous variable glucose infusion rate.
These data were subjected to a smoothing procedure. The glucose concentration and the APE 
of the enriched 2 0 % glucose infusâtes and the glucose concentrations of the tracer infusate 
were all measured and these values used in the calculations.
Clamp protocol
Following screening subjects were assigned the lowest available randomisation number and 
were randomised to a specific treatment sequence in a randomised block design which was 
unknown to the investigator until the day before each study. The study was not blinded. 
Subjects were studied on three separate occasions 7 to 28 days apart. Subjects received 1] 
detemir 9nmol/kg(LD), 2] detemir 18nmol/kg (HD) or 3] human NPH insulin 0.3 lU/kg 
(1.8nmol/kg) (NPH) (Novo-Nordisk) in random order. Subjects with diabetes received a 
higher dose of NPH insulin 0.6IU/kg (3.6nmol/kg) instead of the 0.3 lU/kg (1.8nmol/kg) 
dose. Subjects were asked to have a moderate carbohydrate rich meal the night before the 
clamp. They were not allowed to perform strenuous exercise in the 48 hours preceding the 
study, and were not allowed to consume alcohol for 24 hours before the study. They were
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asked if they had taken any other medication that might interfere with the study drug, or 
suffered any adverse events since the previous visit.
Subjects arrived at 8  in the morning following an overnight (10 hour) fast, they were 
allowed to drink water freely throughout. Those subjects with Type 1 diabetes were asked 
to omit their long/intermediate acting insulin for 24 hours prior to the study day. They were 
given soluble human insulin (actrapid) to take the evening before the study but were asked 
not to take any insulin after midnight the night before the study. Subjects with type 2 
diabetes taking insulin were managed as those with type 1 diabetes. Those on oral 
hypoglycaemic agents were asked to omit their oral hypoglycaemic medication for 48 hours 
prior to the study.
On arrival their blood pressure and pulse were taken supine and standing, they were weighed 
and body fat percentage estimated using electrical impedance (Tanita body fat scales, Tanita 
UK Ltd, Yiewsley, Middlessex). They were then asked to lie or sit on a bed and an 18- 
gauge cannula was inserted into each antecubital fossa if possible (other large veins in the 
forearm or hand were used if there was no suitable vein in the antecubital fossa). One 
cannula was used for blood sampling and one for the administration of the various infusâtes. 
Baseline blood samples were taken, then a priming dose of 170mg [6 ,6 -^H2 ] glucose and 
0.14 mg/kg D5 glycerol was given, followed by a continuous infusion 1.7 mg/min [6 ,6 -^H2 ] 
glucose and 0.5 mg/kg/h D5 glycerol. Subjects with diabetes were given a tapering infusion 
of human soluble insulin to bring their plasma glucose into the normal range (4-7mmol/l). 
The infusion of human soluble insulin was tapered off by 25% from t = -10 to -5 min and by 
a further 50% from t = -5 to 0 min and stopped at t = 0 min.
An 120 minute equilibration period was allowed to reach steady state tracer enrichment 
before taking samples at -30, -20, -10 and time zero. For subjects with diabetes a 130 
minute equilibration period was allowed and baseline blood samples were taken at -40, -30, 
-20, -10 and time zero. Immediately after the blood sample was taken at time zero, subjects 
were dosed with subcutaneous injection of trial insulin, either detemir 9 nmol/kg (LD), 
detemir 18 nmol/kg HD or human NPH insulin 0.3 lU/kg (1.8 nmol/kg) (or 0.6IU/kg for
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subjects with diabetes) (NPH) according to randomisation. Blood samples were taken at 15 
minute intervals for measurement of plasma glucose, this was done at the bedside using a 
blood glucose analyser (YSI 2300), the infusion rate of 20% dextrose (spiked with 400 mg 
[6 ,6 -^H2 ] glucose per 500 ml 20% dextrose) was altered accordingly to clamp blood 
glucose. The blood glucose was clamped between 4.0 mmoll'^ and 5.5 mmoll'^ for 16 hours 
after subcutaneous insulin injection. In healthy subjects blood glucose was clamped to their 
presenting blood glucose on their first study day.
Blood samples for glucose enrichment, insulin, c-peptide, glucagon, IGFBP-1, IGF-1, 
NEFA and glycerol enrichment analyses were taken at regular intervals during the clamp 
(see table 1). Following the 16 hour period the infusions were stopped, cannulae removed 
and the subject was fed a carbohydrate rich meal and allowed to sleep until the following 
morning, when they were allowed home. The clamp studies were then repeated on two 
further dosing days separated by at least 7 days and not more than 28 days. On these dosing 
days the subjects received the other doses according to the randomisation schedule.
34 (35 for subjects with diabetes) samples each requiring 2 ml of blood were taken at regular 
intervals throughout the study for insulin, C-peptide and glucagon analyses. 34 (35 for 
subjects with diabetes) samples each requiring 3 ml of blood were taken for glucose and 
glycerol enrichment. 21 samples each requiring 2 ml blood were taken for IGFBP-1 and 
IGF-1 analyses. A further 15 samples each requiring 1 ml of blood were taken for NEFA 
analysis. Samples for measurement of blood glucose were midway between samples for 
other assays at 15 minute intervals. In total 41 samples requiring 1 ml blood were taken for 
glucose analysis. This is a total of 268 ml blood taken during each clamp study.
All blood samples were put immediately into bottles once the blood was drawn. The bottles 
were then kept on ice. Every hour all the samples on ice were transferred to a refrigerated 
centrifuge and centrifuged at 3060 revolutions per minute (2000g) for 10 minutes. The 
samples were then immediately removed from the centrifuge, pippetted into the appropriate 
aliquots and stored in a freezer at - 2 0  ®C.
54
Blood samples for insulin, insulin detemir, C-peptide and glucagon analysis were sent in 
batches to Medi-lab in Copenhagen where the analyses were made. They were packed in 
dry ice and sent by overnight courier service. Confirmation was received when the samples
arrived that they were still frozen and that the packing cases were intact.
Blood samples for glucose and glycerol enrichment as well as those for NEFA assay were 
transferred in dry ice to St Thomas’ hospital by private transfer. All samples remained 
frozen and were immediately placed in the freezer to await analysis.
Blood samples for analysis of IGFBP-1 and IGF-1 were kept at the Royal Surrey County
Hospital where the assays took place.
Table 1.
Blood Sampling Times
Time
Insulin,C-peptide 
SGIucagon
Glucose and Glycerol Concentration and 
enrichment NEFA
IGF-
1&IGFBP-1
-160 X X X X
-40 X X
-30 X X
-20 X X
-10 X X X X
0 X X X X
30 X X X X
60 X X X X
90 X X X X
120 X X X X
150 X X X X
180 X X X
210 X X
240 X X X X
270 X X
300 X X X X
330 X X
360 X X X X
390 X X
420 X X X
450 X X
480 X X X
510 X X
540 X X X X
570 X X
600 X X X
630 X X
660 X X X
690 X X
720 X X X X
750 X X
780 X X X X
840 X X X X
960 X X X X
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Preparation of tracer solutions
Tracer solutions of [6 ,6 -^H2] glucose and [^Hs] glycerol (both 99% enrichment, sterile and 
pyogen free from Phenome Siences Inc, Woburn, M.A., U.S.A. were used.
Laboratory assessments
Glucose concentration and enrichment
Blood samples were taken in fluoride oxalate tubes and whole blood initially and then 
plasma glucose concentrations were measured on YSI 2300 STAT plus glucose analyser 
(Yellow Springs instruments. Yellow Springs, Ohio). This method is based on glucose 
oxidation. 25 pi of blood or plasma is aspirated by a sipper, which then transfers and injects 
the sample into a buffer filled sample chamber. Some of the substrate diffuses through the 
membrane where it contacts the immobilized oxidase enzyme, it is rapidly oxidised 
producing hydrogen peroxide (reaction 1 )
Reaction 1
P-D-glucose + O2 glucose oxidase Glucono-Ô-lactone + H2O2
The hydrogen peroxide (H2O2) is in turn oxidised at the platinum anode producing electrons 
(reaction 2 )
Reaction 2
H2O2 2 H^ + O2 + 2  e
A dynamic equilibrium is achieved when the rate of H2O2 production and the rate at which 
H2O2 leaves the immobilised enzyme layer are constant and is indicated by a steady state 
response. The electron flow is linearly proportional to the steady state concentration and
56
therefore the concentration of glucose. The platinum electrode is held at anionic potential 
and is capable of oxidising many substances other than H2O2 . To prevent these reducing 
agents from contributing to the sensor current the membrane contains an inner layer 
consisting of a very thin film of cellulose acetate. The film readily passes H2O2 but excludes 
chemical compounds with molecular weights above approximately 200. The analyser was 
calibrated before use using glucose standard solution 25 mmol/1, and standard normal and 
pathological serum with glucose concentrations of 4.5 mmol/1 and 13 mmol/1 respectively.
[6 ,6 -^H2] Glucose analysis
Glucose isotopic enrichment was determined by gas chromatography-mass spectrometry 
(GC-MS) on a VG Trio-2 5890 (Hewlet-Packard, Woking, UK) using selected ion 
monitoring of a glucose acetate boronate derivative (Bier et al, 1977). The samples were 
first deproteinised by adding 50 pi of plasma sample to 0.5ml of ethyl alcohol and 
centrifuging at 1000 rpm for 5 min. The supernatant was then removed and dried under a 
continuous stream of N 2 at 50 °C. The glucose acetate boronate derivative was produced by 
adding butylboronic acid in pyridine (10 mg/ml), heating this solution at 95°C for 30 min 
and then cooling at room temperature. Acetic anhydride (100 pi) was then added and the 
mixture left for 1 hour again at room temperature. This solution was dried under N2 and 
dissolved in 500 pi of decane before being introduced into the GC-MS. The ions monitored 
were of mass 297 and 299 representing [M-C4H9]  ^and the corresponding fragment enriched 
with two deuterium atoms respectively. The within assay coefficient of variation of 
measurement of isotopic enrichment was < 2 %.
Glycerol concentration and enrichment
0.5 ml plasma was pipetted into plastic tubes and 1ml 3.5%SSA was added. Samples were 
mixed and then allowed to stand for 15 to 30 minutes. They were then centrifuged at 2000 
rpm for 20 minutes at 4®C. Meanwhile the ion exchange columns were prepared; 0.5 ml of
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cation resin was added first to the column, then rinsed with 1 ml of distilled water, then 0.5 
ml of anion resin was added and rinsed with 1 ml of distilled water. The supernatant from 
the centrifuged tubes was then added to the columns and the elute collected in labelled vials. 
Each column was rinsed with 3 ml distilled water. The vials were covered with parafilm and 
frozen at -20®C. The samples were dried under a stream of dried compressed air at room 
temperature until approximately 200pl of liquid remained (around 15 hours). At that point, 
the sample temperature was increased to 50°C while continuing the air stream until the 
sample completely dried (around 2 hours). lOOpl of pyridine and lOOpl of MTBSTFA were 
added to the dried residue, and the mixture was vortexed. The solution was allowed to 
remain at room temperature for 30 minutes allowing derivatisation to reach completion. The 
derivatised sample was transferred into a plastic micro-injection autosampler vial and was 
sealed.
After a 2- pi splitless injection of the derivatised sample onto the column, the oven was held 
at the initial temperature of 100°C for 0.5 minutes, increased to 300°C at 25 °C /min and 
maintained at 300 °C for 1.5 min. Thus the total run time was equal to 10 minutes with 
glycerol and 5D glycerol eluting at 6  minutes. Using SIM, the major fragments monitored 
for the tBDMS derivatives of glycerol and d5-glycerol were the [M-57] ion fragments, 
377m/z and 382m/z respectively. With d5-glycerol used as the tracer, the enrichment 
quantitated in plasma as the ratio of d5-glycerol:glycerol (ion abundance o f 377/382 m/z).
NEFA
NEFA was measured using the Wako NEFA C assay on the Cobas Fara II (Roche, 
Welwyn Garden City, UK.) the method of which relies upon the acylation of coenzyme 
A(CoA) by the fatty acids in the presence of added acyl-CoA synthetase (ACS). The acyl- 
CoA produced is oxidized by added acyl-CoA oxidase (ACOD) with the generation of 
hydrogen peroxide. Hydrogen peroxide, in the presence of peroxidase (POD) permits the 
oxidative condensation of 3-methyl-N-ethyl-N-(b-hydroxyethyl)-aniline (MEHA) with 4- 
aminoantipyrine to form a purple color which can be measured spectrophotometrically at ' 
550nm.
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The within-run precision for this assay is 2.7%CV, 1.1 %CV and 1.1%CV for mean 
concentrations of 0.33mmol/L, 0.62mmol/L and 0.99mmol/L, respectively. The linear 
range of the assay is 0-2.0 mmol/L.
Insulin & insulin detemir, C-Peptide and Glucagon
The following assays were done at Medilab by the request of Novo Nordisk. Insulin detemir 
was measured using the ELISA specific insulin detemir assay (Heineman et al 1999). 
Human insulin was measured using the DAKO insulin ELISA assay (Inter-assay CV 4.2- 
9.3%). C-peptide and glucagon were measured using DAKO ELISA assays (Inter-assay CV 
3.3-5.7% for C-Peptide and 6 % for glucagon).
IGF-1
lGF-1 was measured using Nichols institute Diagnostics chemiluminescence immunoassay. 
This assay is a two site chemiluminescence assay for the measurement of lGF-1 in human 
serum. Acridium esters emit light upon treatment with hydrogen peroxide and an alkaline 
solution. The Trigger 1 solution contains hydrogen peroxide in dilute acid and Trigger 2 
solution contains dilute sodium hydroxide. The system automatically injects Trigger 
solutions 1 and 2 into the wells which oxidse the acridium ester. The oxidised product is in 
an excited state. The subsequent return to the ground state results in emission of light which 
is quantified in 2 seconds and is expressed in relative light units (RLU) by the intergrated 
system luminometer. The antibody to the C-terminal with the amino acid sequences of 62- 
70 is biotinylated for capture and the antibody to the amino acid sequences of 1-23 and 42- 
61 is labelled with acridium ester for detection.
The patient sample is acidified to separate lGF-1 from IGFBPs, then excess lGF-11 is added 
in the assay to block IGFBP binding sites from recombining with the released lGF-1. The 
acidified patient sample is incubated simultaneously with the biotinylated capture antibody, 
excess lGF-11, and the acridium ester labelled tag antibody. During the first incubation.
59
IGF-1 in the sample forms a sandwich complex with the capture antibody and the acridium 
labelled antibody. After the initial incubation period streptavidin coated magnetic particles 
are added to the reaction mixture and a second incubation follows. The streptavidin coated 
magnetic particles allow for a highly specific and efficient means of binding the sandwich 
complex to the solid phase via the high affinity interaction between biotin and streptavidin. 
Free labelled antibody is separated from the labelled antibody bound to the magnetic 
particles by aspiration of the reaction mixture and subsequent washing. The wells 
containing the washed magnetic particles are transported to the system luminometer, which 
automatically injects Trigger 1 and Trigger 2, initiating the chemiluminescence reaction. 
The light is quantitated by the luminometer and expressed as RLU. The amount of bound 
labelled antibody is directly proportional to the concentration of IGF-1 in the sample.
The assay runs on the Nichols advantage speciality system. The sample is placed in the 
designated sample racks and these racks placed in the sample loading area. The system 
performs an assay specific on board dilution by first pipetting 13 pi of the sample and 400 
pi of the acidification buffer into one well of the cuvette. 50 pi of the acidified sample 
mixture is then pipetted and added to a mixture of 1 0 0  pi of of biotinylated goat polyclonal 
antibody, 50 pi of the IGF-II solution and 50 pi of the acridium labelled goat polyclonal 
antibody in the next well of the cuvette. The cuvette strip is transported to the incubation 
chamber and incubated for 20 minutes at 37®C. After this initial incubation, 25 pi of 
streptevidin coated magnetic particles are added to each well. The incubation is prolonged 
for a further 10 minutes at 37®C. After the entire incubation the wells are washed and 
measured in the measuring chamber. The coefficient of variation for this assay was 4.8%.
IGFBP-1
IGFBP-1 was measured using Oy Medix Biochemica Ab IGFBP-1 lEMA test. The 
principle of this test is as follows. A monoclonal antibody specific to IGFBP-1 is 
immobilized on microwell plates, and another monoclonal antibody, also specific to IGFBP- 
1, is conjugated with horse-radish peroxidase (HRP). IGFBP-1 from the sample is bound to 
the plates. After a washing step, HRP is added. After a second washing step, enzyme
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substrate is added. The enzymatic reaction is proportional to the amount of IGFBP-1 in the 
sample. The reaction is terminated by adding stopping solution. Absorbance is measured 
on a plate reader.
80 pi of assay buffer was pipetted into each well. 2 0  pi of the serum sample was then 
pipetted into the well. The plate was covered and incubated for 30 minutes at room 
temperature on a plate shaker. The wells were then aspirated and washed 3 times with 300 
pi of washing solution. 1 0 0  pi of enzyme conjugate was then pipetted into the wells and the 
plate covered and incubated for a further 30 minutes at room temperature on the plate 
shaker. The wells were then washed again as above and 100 pi of HRP solution was added 
to each of the wells. The plate was covered again and incubated for 10 minutes at room 
temperature on the plate shaker. The reaction was stopped by adding 50 pi of stopping 
solution to each of the wells. The plate was shaken gently to mix the solutions. The 
absorbance at 414 nm was then measured using a plate reader. The inter-assay CV was 
6.4%.
Trial design 
Type of trial
We performed a single centre randomised open label three period crossover trial with 
subcutaneous injections of insulin detemir and NPH insulin using a euglycaemic clamp with 
labelled glucose in healthy subjects and in subjects with Type 1 and Type 2 diabetes 
mellitus. Insulin detemir was given in doses that were expected to cause the same blood 
glucose lowering effect as the dose of NPH administered. An additional dose o f insulin 
detemir was also studied. In healthy subjects this additional detemir dose was higher than 
the comparative doses, but in the diabetic subjects the additional detemir dose was lower.
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Rationale for trial design
The trial was open labelled. The insulins have different appearances and it was therefore not 
possible to blind the trial. The crossover design was chosen to minimise the number of 
subjects needed as each subject then becomes their own control and intra-subject variation is 
smaller than inter-subject variation.
A clamp procedure with no pre-dose insulin infusion was used for healthy subjects. Type 1 
and Type 2 diabetic subjects were expected to enter the trial sessions with high blood 
glucose levels and thus the main issue was to lower their fasting blood glucose to predefined 
clamp level. In order to obtain a clamp level as normal as possible, an insulin infusion was 
started at the same time as the glucose and glycerol infusion. This insulin infusion was 
tapered off before administration of the trial drug. Intravenous administered insulin is 
rapidly eliminated and the effect on the endpoints of the trial was considered minimal. The 
effect has been evaluated. Each subject was clamped at the same level at each visit.
Free fatty acid lipogenesis generally takes place immediately following an increase in 
insulin concentration and stops when insulin levels are low. Measurements of NEFA were 
made during the first hours after trial drug administration, at the maximum concentration 
and during the last hours of the study. The concentrations of IGF-1 and IGFBP-1 were 
measured hourly.
Rationale for dosage regimen
The effect of two dose levels of insulin detemir was investigated in order to allow for a dose 
response relationship to be generated. One dose level of NPH insulin was administered for 
comparison, and it was hoped that this dose would be equipotent to one of the detemir doses. 
Pharmacodynamic trials with insulin detemir in healthy subjects indicated a difference in 
blood glucose lowering potency of approximately a factor of five between insulin detemir 
and NPH insulin. Thus the dose of insulin detemir expected to give the same blood glucose 
lowering effect as NPH 0.3 lU/kg (1.8 nmol/kg) was 9 nmol/kg. The second dose of insulin
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detemir was 18 nmol/kg and expected to give a similar blood glucose lowering effect as 
NPH 0.6 lU/kg (3.6 nmol/kg).
Trial population
Number of subjects in each group
Sample size calculation was based on the peripheral glucose uptake (PGU) in a two-period 
two-treatment sub-design of the three periods. Intrasubject coefficient of variation (CV) was 
assumed to be maximum 25%. Considering a relative difference of 50%, and using a 
significance level of 5%, the power would be 85% if eight subjects completed the trial and 
70% if six subjects completed the trial.) Based on this sample size calculation eight subjects 
were included in the trial. If more than two subjects were withdrawn, replacement subjects 
were to be enrolled in order to obtain at least six completing subjects in each group (healthy 
subjects and subjects with Type 1 and Type 2 diabetes). Therefore 18 subjects completing 3 
studies.
Subjects were recruited based on the following inclusion and exclusion criteria:
Inclusion criteria 
Healthy subjects
Signed informed consent obtained before any trial related activity.
Healthy male and female subjects between 19 and 60 years inclusive.
Considered generally healthy upon completion of medical history and physical examination. 
Body mass index <30kg/m^
Fasting blood glucose < 6  mmol/1
Subjects with type 1 diabetes as above and/or 
Age> 18 years
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Type 1 diabetes according to ADA criteria (see introduction) 
Duration of diabetes >12 months 
HbAic < 12 %
C-peptide negative
Subjects with type 2 diabetes
Type 2 diabetes according to ADA criteria (see introduction)
Duration of diabetes >12 months
Age >35 years
BMI < 35 kg/m2
H bA ic<12%
Exclusion criteria 
Healthy subjects
Participation in any other clinical trial involving other investigational products within the 
last 3 months
Clinically significant abnormal haematology or biochemistry screening tests.
Any serious systemic infectious disease that occurred during the four weeks prior to the first 
dose of the trial drug.
Any intercurrent illness that may effect blood glucose 
Subject with a history of drug or alcohol dependence.
Use of prescription drugs except oral contraceptives within 3 weeks prior to the first dose of 
the trial drug.
Use of non prescription drugs, except ordinary vitamin preparations within 3 weeks of the 
first dose of the trial drug. Occasional use of analgesics was allowed up to 48 hours prior to 
entrance in the clinical research centre.
Mental incapacity, unwillingness or language barriers precluding adequate understanding or 
cooperation.
Blood donation of more than 500ml within the last 12 weeks.
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Subjects with a first degree relative with diabetes mellitus.
History or presence of diabetes, cancer or any clinically significant cardiac, respiratory, 
metabolic, renal, hepatic, gastrointestinal, endocrinological, dermatological, venereal 
haematological, neurological or psychiatric disorder.
Previous anaphylactic reaction
History of significant drug allergy or hypersensitivity.
Females of child bearing potential not using an acceptable method of contraception which 
include an intrauterine device (lUD) which has been in place for at least 3 months, or 
sterilisation, or the oral contraceptive pill which should have been taken without difficulty 
for at least 3 months or an approved hormonal implant or barrier methods.
Subjects with type 1 diabetes above and/or
Laser therapy for retinopathy within the last two months
Current treatment with systemic corticosteroids
Impaired hepatic fiinction measured as alanine aminotransferase (ALAT) > two times the 
upper reference limit
Impaired renal function measure as creatinine >150 pM (1.7 mg/dL)
Cardiac problems defined as: 1) decompensated heart failure (New York Heart Association 
class III and IV) and/or 2) angina pectoris and/or 3) myocardial infarction at any time 
Uncontrolled treated/untreated hypertension as judged by the investigator
Subjects with type 2 diabetes as above and 
Total insulin dosage >120 lU/day
Safety visit
Before screening took place the subjects were provided with written and oral information 
about the study and the procedures involved. They were asked to sign an informed consent 
form. All subjects were then asked a series of questions to determine their eligibility for the 
trial with respect to the inclusion and exclusion criteria. The subject’s demographics (date 
of birth, sex, ethnic origin and smoking habits) were recorded. A full medical history was
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taken and the subject examined. The subject’s height and weight were recorded and their 
body mass index calculated. Blood pressure and pulse were also measured and an 
electrocardiograph (ECG) recorded. Blood was then taken for haematology and clinical 
chemistry, and a urine sample sent for urinalysis and pregnancy test if relevant.
If the subject fulfilled all of the inclusion and exclusion criteria they were accepted into the 
trial and an appointment was made for visit two within 5-21 days. Screen failures were 
logged.
Subjects passing screening went on to perform the study days, which were held 7 to 21 days 
apart from each other and were as described above.
Statistical analyses
Glucose Ra and Rd were calculated using a modified form of the Steele equation (Steele, 
1959) adapted by Finegood et al, (1987) to account for the addition of stable labelled tracer 
to the exogenous glucose infusate. The volume of distribution was 220 ml/kg and ratio of 
effective glucose to actual space was 0.65. Glycerol Ra was calculated using the Steele 
equation with a volume of distribution of 230ml/kg. Glucose Ra and Rd expressed as a 
percentage of GIR at each time point was averaged over 960 minutes to determine the 
proportion of the glucose lowering effect of each insulin due to a decrease in Ra and the 
proportion due to an increase in Rd. All values are expressed as mean ± SEM. Statistical 
analysis of the results was either by a 2 way ANOVA with subjects and treatment as factors 
using baseline as a covariate or a paired students t-test.
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Chapter 3 
Results
Healthy Subjects
Subject demographics
10 healthy subjects 5 female and 5 male were screened. 4 female subjects and 4 male 
subjects were randomised for the study. One male subject failed screening because he was 
taking regular inhaled corticosteroids for asthma. One female subject passed screening, but 
withdrew from the study before the first clamp. One female subject completed one clamp 
study and then withdrew from further studies after finding the clamp procedure too arduous, 
her results have not been included in the analysis as the data were not paired. 3 female 
subjects and 4 male subjects completed all three clamps, they were aged 29.9 ± 3.4 years 
with BMI 22.9 ± 0.72 kg/m^, they weighed 68.01 ± 2.88 kg and a body fat percentage of 
24.71 ± 4.14 %. One of the subjects completing all three study days was not fasting for the 
high dose study day. The results for this study have therefore not been included in our 
analysis. The results presented therefore are for six subjects for high dose, and seven for 
low dose and NPH.
Plasma Glucose
Euglycaemia was maintained throughout all clamp studies, there was no difference between 
the plasma glucose during the three studies. Mean plasma glucose was clamped at 
4.92+0.11, 4.95+0.08 and 5.01±0.14mmol/l in the LD, NPH and HD studies respectively. 
The mean and standard differences of the individual coefficient of variation for glucose
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during the clamp studies was 4.95+1.82 % for LD, 6.32±2.34 % for NPH and 7.82±3.76 % 
for HD.
Figure 10. Graph of healthy subjects mean plasma glucose.
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Glucose Infusion Rate
The total amount of glucose infused to maintain euglycaemia was similar for LD (2019 ± 
374 mg/kg) and NPH (2102 ± 384 mg/kg)) (p=NS) demonstrating their equipotency (Fig 
11). There was no difference between LD and NPH in the time to starting the glucose 
infusion, peak glucose infusion rate or glucose infusion rate at 960 minutes. Glucose was 
infused earlier following HD (40+7.5 min) than LD (61 ±9.6 min, p<0.03). The peak 
glucose infusion rate following HD was higher (5.7±0.82 mg/kg/min) than LD (3.68+0.72 
mg/kg/min, p<0.03). Total glucose infused was significantly higher following HD 
(3267±388mg/kg) than LD (p<0.02). (Table 2)
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Table 2. Healthy Subjects Plasma Glucose and Glucose Infusion Rate.
LD NPH HD
Plasma Glucose 
mmol/1
4.92 ±0.11 4.95 1  0.08 5.0110.14
Total Amount of Glucose Infused, 
mg/kg
20191374* 21021384 32671388
Time to Start of Glucose Infusion, 
minutes
61 ±9.45* 6417.18 4017.35
Peak Glucose Infusion Rate, 
mg/kg/min
3.68 ± 0.72 * 4.0410.73 5.710.82
Glucose Infusion Rate At 960 
minutes, mg/kg/min
1.6410.23 * 1.4210.15 2.92 1 0.44
* Indicates a statistically significant difference between LD and HD. 
** Indicates a statistically significant difference between LD and NPH. 
***Indicates a statistically significant difference between NPH and HD.
Figure 11. Graph of healthy subjects mean glucose infusion rates
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Glucose Metabolism
The minimum glucose Ra was significantly lower (p<0.02) with LD (-0.10±0.15 
mg/kg/min) than NPH (0.17±0.10 mg/kg/min) (Fig 12). Using ANOVA, glucose Ra with 
LD was significantly lower than with NPH (mean difference 0.24mg.kg'\min'^)(CI 0.09, 
0.39)(p<0.01). This difference was still significant (p<0.05) when corrected for baseline 
(mean difference 0.25 mg.kg'\min"^ Cl 0.05, 0.44) using analysis of covariance.
Figure 12. Graph of healthy subjects mean glucose rate of appearance.
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The mean of the maximum change from baseline of glucose Rd (for each individual) was 
lower with LD (1.52±0.49 mg/kg/min) than NPH (1.97+0.52 mg/kg/min) but this did not 
reach statistical significance.
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Figure 13. Graph of healthy subjects mean glucose rate of disappearance.
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Figure 14. Graph of healthy subjects mean glucose Ra and Rd.
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Of the mean glucose lowering effect of insulin detemir over the 960 minutes (i.e. the 
proportion of glucose infused needed to overcome each of Ra and Rd) 71.3±4% was due to 
the decrease in Ra and 28.7±4% was due to the increase in glucose Rd, whereas for NPH 
this was 63.3+3.9% from the decrease in Ra and 36.7+3.9% from the increase in Rd
(p<0 .0 1 ).
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Figure 14. Bar charts showing the relative proportion of glucose lowering effect of each
insulin from effect on glucose Ra and glucose Rd.
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Figure 15. Pie chart showing the overall mean proportion of effect of each insulin on
glucose Ra and Rd.
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The maximum Rd for HD was 5.21±0.71 mg/kg/min which was significantly greater than 
with LD (p<0.03). HD appeared to suppress glycerol Ra more than LD but this difference 
did not reach statistical significance. The maximum change from baseline was -1.31+0.20 
pmol/kg/min with HD.
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Table 3. Healthy Subjects Glucose Metabolism
LD NPH HD
Baseline Ra mg/kg/min 2.01 ±0.12 2.17 ±0.09 1.68 ±0.15
Minimum Ra mg/kg/min -0.10 ±0.15** 0.17±0.10 -0.69 ±0.16
Maximum change from 
baseline R a mg/kg/min
-2.10 ±0.24 -2.00 ±0.18 -2.37 ± 0.26
AOC Ra mg/kg 1401.48 ±147.99 1328.69 ±135.80 1515.81 ±213.29
Baseline Rd mg/kg/min 2.06 ±0.12 2.18 ±0.08 1.75 ±0.18
Maximum Rd 
mg/kg/min
3.58 ±0.54* 4.15 ±0.58 5.25 ±0.74
Maximum change from 
baseline Rd mg/kg/min
1.52 ±0.49 1.97 ±0.52 3.51 ±0.75
AUC Rd mg/kg 564.42 ± 252.93 760.46 ± 247.27 1767.85 ±431.14
* Indicates a statistica ly significant difference between LD and HD.
** Indicates a statistically significant difference between LD and NPH. 
***Indicates a statistically significant difference between NPH and HD.
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Figure 16. Graph of Healthy Subjects Glucose Tracer:Tracee ratio during the clamp studies
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Glycerol metabolism
Mean glycerol Ra at baseline was similar with the three study doses at 1.75 ± 0.15 
pmol/kg/min for LD, 1.91 ±0.33 pmol/kg/min for NPH and 1.94 ± 0.41 pmol/kg/min for 
HD (p=NS). The point of maximum suppression following dosing was 0.93 ± 0.18 
pmol/kg/min for LD, 0.81 ±0.18 pmol/kg/min for NPH and 0.63 ± 0.07 pmol/kg/min for 
HD (p=NS). The maximum change from baseline for glycerol Ra was -0.82 ± 0.17 
pmol/kg/min with LD, -1.10 ± 0.24 pmol/kg/min with NPH and 1.31 ± 0.20 pmol/kg/min 
with HD. The area over the curve (AOC) effect on glycerol Ra was less for low dose than 
NPH or high dose detemir, although not statistically significant. Following dosing with LD 
AOC was -366.1 ± 145.52, following NPH it was -691.0 ± 215.44 and following HD it was 
-945.6 ± 172.28.
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Table 4. Healthy Subjects Glycerol Metabolism.
LD NPH HD
Baseline Ra pmol/kg/min 1.75 ±0.15 1.91 ±0.33 1.94 ±0.41
Minimum Ra pmol/kg/min 0.93 ±0.18 0.81 ±0.18 0.63 ±0.07
Maximum change from 
baseline Ra pmol/kg/min
-0.82 ±0.17 -I.10±0.24 1.31 ±0.20
AOC Ra pmol/kg -366.1 ±145.52 -691.0 ±215.44 -945.6 ± 172.28
* Indicates a statistically significant difference between LD and I ID.
** Indicates a statistically significant difference between LD and NPH. 
***Indicates a statistically significant difference between NPH and HD.
Figure 17. Graph of healthy subjects mean rate of appearance of glycerol.
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NEFA
All three insulin doses suppressed NEFA concentrations. Plamsa NEFA concentrations at 
baseline were 0.65 ± 0.08 mmol/1 for LD, 0.52 ±0.11 mmol/1 for NPH and 0.52 ± 0.12 
mmol/1 for HD (p=NS). There was significantly more suppression of NEFA concentration 
with NPH than with LD (mean difference O.lOmmol/1 Cl 0.03, 0.17)(ANOVA, p<0.02). 
However there was no significant difference in the minimum NEFA concentrations 
following LD (0.12 ± 0.04 pmol) or NPH (0.09 ± 0.03 pmol). Plasma NEFA concentration 
following HD was significantly lower than with LD (ANOVA, p<0.01).
Table 5. Healthy Subjects NEFA results.
LD NPH HD
Baseline NEFA pmol/l 0.65 ± 0.08 0.52 ±0.11 0.52 ±0.12
Maximum change from 
baseline NEFA pmol/1
0.54 ± 0.08 0.43 ±0.11 0.48 ±0.11
AOC NEFA pmol/1 -305.83 ± 59.8 -252.79 ± 89.9 -340.32 ± 90.73
* Indicates a statistically significant difference between LD and HD. 
** Indicates a statistically significant difference between LD and NPH. 
***lndicates a statistically significant difference between NPH and HD.
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Figure 19. Graph of healthy subjects mean plasma NEFA concentrations.
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IGF-1
IGF-1 levels did not alter during the studies. Mean IGF-1 levels at baseline were 24.15 ± 
3.43 nmol/1 for LD, 24.97 ± 2.68 nmol/1 for NPH and 26.5 ± 2.98 nmol/1 for HD. Mean 
IGF-1 level following injection with LD was 23.01 ± 2.46 nmol/1, 25.02 ± 2.53 nmol/1 for 
HD and following NPH injection it was 24.13 ± 2.46 nmol/1, there was no difference 
between these three groups.
Table 6. Healthy Subjects IGF-1 results.
LD NPH HD
Baseline IGF-1 concentration nmol/1 24.15+3.43 26J±:L98 24.97 ±2.68
Mean IGF-1 concentration nmol/1 23.01 ±2.46 24.13 ±2.46 25^ 2± 2^ 3
* Indicates a statistically significant difference between LD and HD.
** Indicates a statistically significant difference between LD and NPH. 
***Indicates a statistically significant difference between NPH and HD.
Figure 20. Graph of healthy subjects mean plasma IGF-1 concentrations.
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IGFBP-1
IGFBP-1 levels were suppressed by insulin. Mean IGFBP-1 levels at baseline were 7.25 ± 
3.7 pg/l for LD, 3.08 ± 0.41 pg/1 for HD and 5.96 ± 3.48 pg/l for NPH study day. There 
was no significant difference between these baseline values. They fell to a mean minimum 
value of 1.76 ± 0.87 pg/1 following LD, 0.9 ± 0.65 pg/1 following HD and 1.57 ± 0.60 pg/1 
following NPH insulin. The mean minimum was significantly lower following high dose 
detemir than following low dose detemir (p<0.03), however it was not significantly different 
to the mean minimum following NPH. There was no difference between the mean 
minimums following NPH and low dose detemir. Using analysis of variance there was no 
difference between the three insulins on effect on IGFBP-1 levels.
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Table 7. Healthy Subjects IGFBP-1 results.
LD NPH HD
Baseline IGFBP-1 concentration pg/l 7.25 + 3.7 5.96 ±3.48 3.08 ±0.41
Minimum IGFBP-1 Plasma 
concentration pg/1
1.76 ±0.87* 1.57 ±0.60 0.9 ±0.65
* Indicates a statistically significant difference between LD and HD.
** Indicates a statistically significant difference between LD and NPH. 
***Indicates a statistically significant difference between NPH and HD.
Figure 21. Graph of healthy subjects mean plasma IGFBP-1 concentrations.
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Insulin and insulin detemir
Mean AUC (0-960mins) was 1350.8±125.8, 2220.4+417.5 and 81.4±11.7 nmol.F^ x min for 
LD, HD and NPH respectively. There was no individual difference in the time to reach 
maximum concentration (Tmax) for the three insulins being 617+85 mins, 520±79 mins and 
420±60 mins for LD, HD and NPH respectively. The maximum concentration (C max) was 
greater for HD (4478±190 pmolf^) than LD (2345+222 pmolF*) (p<0.01). C max for NPH 
was 122±14 pmolf \  A doubling in insulin detemir dose resulted in an approximately two­
fold increase in AUC and Cmax
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Figure 22. Graph of healthy subjects mean plasma insulin and insulin detemir
concentrations.
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C-Peptide
C-peptide at baseline was similar in each insulin study being 0.47±0.04 nmol/1, 0.55±0.08 
nmol/1 and 0.31 ±0.13 nmol/1 for LD. NPH and HD respectively. C-peptide suppressed 
following each insulin and there was no difference in this suppression between the insulins 
with minimum c-peptide 0.25+0.05 nmol/1, 0.27+0.05 nmol/1 and 0.15+0.06 nmol/1 
following LD, NPH and HD respectively.
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Figure 23. Graph of healthy subjects mean plasma c-peptide concentrations.
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Glucagon
The glucagon plasma concentrations did not change after dosing with insulin detemir and 
NPH insulin, and there was no difference between insulin detemir and NPH insulin.
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Type 1 Subjects 
Subject demographics
5 male subjects and one female subject passed screening. The female subject suffered a 
serious adverse event (cellulitis from infected cannulation site) following her second clamp 
and did not complete her third clamp (the low dose study). Mean age of subjects 29.5 ± 2.39 
years, they had had diabetes for 15.3 ± 3.86 years, they had reasonable diabetes control with 
HbAlc of 8.45 ± 0.43 %. Their weight was 75.5 ± 1.83 kg and body fat percentage 21.5 ± 
349%^
Plasma Glucose
Subjects arrived for the study day with high blood glucose concentrations having omitted 
their long acting insulin for the previous 24 hours. However there was no difference in 
plasma glucose levels on arrival for the study days. Plasma glucose levels were brought into 
the clamp range using a tapering dose of soluble insulin. There was no difference in the 
soluble insulin infusion rates on the separate dosing days. There was no difference in 
plasma glucose concentrations following the subcutaneous administration of insulin (ie 
during the clamp period) being 6.56 ± 0.21 mmol/1 following HD, 6.64 ± 0.2 mmol/1 
following NPH and 6.55 ±0.19 mmol/1 following LD. The mean and standard differences of 
the individual coefficient of variation for glucose during the clamp studies was 8.77±2.55 % 
forLD, 13.35±5.31 % for NPH and 9.14±1.65 % for HD.
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Figure 24, Graph of Type 1 Subjects Mean Plasma Glucose.
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Glucose infusion rate
There was no difference in the time to starting glucose infusion between the 3 insulins with 
time to start at 89 ± 26.5 mins for HD, 95.3 ± 24.0 for NPH and 136.4 ± 34.5 for LD. The 
maximum glucose infusion rate was similar for the two equipotent doses at 2.9 ± 0.54 
mg/kg/min for HD and 4.64 ± 0.79 mg/kg/min for NPH (p=NS), but lower following LD at 
2.24 ± 0.47 mg/kg/min than NPH (p<0.04). There was no difference in the maximum GIR 
following HD and LD. There was no difference in the time to reach maximum GIR for the 
three insulins, nor was there a difference between the areas under the curve of GIR . AUC 
for HD was 1537.04 ± 279.2 mg/kg, for NPH it was 2015.14 ± 407.7 mg/kg and for LD it 
was 1019.4 ± 266.9 mg/kg. The GIR at the end of the studies was significantly lower 
following LD administration at 0.11 ± 0.11 mg/kg/min than following HD at 1.45 ± 0.51 
mg/kg/min (p<0.05), but not different to NPH at 0.91 ± 0.50 mg/kg/min.
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Table 8. Type 1 Subjects Plasma Glucose and Glucose Infusion Rate.
LD NPH HD
Plasma Glucose mmoI/1 6.55 ±0.19 6.64 ± 0.2 6.56 ±0.21
Time to start of glucose 
infusion mins
136.4 ±34.5 95.3 ±24.0 89 ± 26.5
Maximum glucose infusion 
rate mg/kg/min
2.24 ±0.47 ** 4.64 ± 0.79 2.9 ±0.54
Area under the curve mg/kg 1019.4 ±266.9 2015.14 ±407.7 1537.04 ±279.2
Glucose infusion rate at 960 
mins
0.11 ±0.11 * 0.91 ±0.50 1.45 ±0.51
* Indicates a statistically significant difference between LD and LID.
** Indicates a statistically significant difference between LD and NPH. 
* Revindicates a statistically significant difference between NPH and HD.
Figure 25. Graph of Type 1 Subjects Mean Glucose Infusion Rates.
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Glucose Metabolism
There was no differenee in hepatic glucose output (Ra) at baseline for the 3 insulins being 
2.14±0.40 mg/kg/min for LD, 1.94±0.19 mg/kg/min for HD and 2.14± 0.18 mg/kg/min for 
NPH. These insulins had similar effects suppressing glucose Ra with a mean change from 
baseline o f -2.19+0.45 mg/kg/min for LD, -2.20 ± 0.30 mg/kg/min for HD and -2.53 ± 0.36 
mg/kg/min for NPH (p=NS). Areas over the curve for suppression of Ra was also similar 
between the 3 insulins being -1452.33± 401.61 mg/kg for LD, -1452.71 ± 268.83 mg/kg for 
HD and-1461.18 ± 288.18 mg/kg for NPH (p=NS).
Figure 26. Graph of Type 1 Subjects Mean Glucose Rate of appearance.
Type 1 Subjects Glucose Rate of Appearance (Ra)
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There was no difference in peripheral glucose uptake (Rd) at baseline for the 3 insulins 
being 1.93± 0.42 mg/kg/min for LD, 2.02 ± 0 .17  mg/kg/min for HD and 1.99 ± 0.20 
mg/kg/min for NPH (p=NS).
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Figure 27. Graph of Type 1 Subjects Mean Glucose Rate of Disappearance.
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There was significantly greater effect on change of Rd from baseline following NPH than 
either HD (p<0.03) or LD (p<0.01), with the mean maximum change from baseline being 
0.29 ± 0.46 mg/kg/min for LD, 0.83 ± 0.31 for HD and 2.22 ± 0.41 mg/kg/min for NPH. 
There was no difference between HD and LD for change from baseline. There was also 
significantly greater areas under the curve of Rd following NPH than HD (p<0.01) being 
-234.32 ± 350 mg/kg for LD, 55.74 ± 197.5 mg/kg for HD and 678 ± 138.14 mg/kg for 
NPH. There was no difference between the AUC for HD and LD nor LD and NPH (there 
was great inter-subject variability in the AUC for LD).
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Figure 28. Graph of Type 1 Subjects Mean Glucose Ra and Rd.
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Blood glucose was controlled before the injection of subcutaneous insulin by using 
intravenous soluble insulin. The infusion was stopped just before the subcutaneous insulin 
was injected. This technique led to poor maintenance of euglycaemia in the first 60 minutes 
of the clamp. We have therefore calculated areas under/over the curve for Ra and Rd using 
a baseline of 60 minutes post injection (ie calculating change from the 60 minute value). 
The area over the curve (calculated in this way) of suppression of Ra was not significantly 
different for insulin detemir (1057.8 ± 129.6 mg/kg) compared to NPH (1060.5 ± 188.8 
mg/kg (p=NS). The area under the glucose Rd curve (from T=60) was also not significantly 
different for the two insulins at 322.2 ± 197.1 mg/kg for detemir and 930.4 ± 290.7mg/kg 
for NPH (p=0.06).
Figure 29. Graph of Type 1 Subjects Mean Glucose Ra and Rd Shown as change from 60 
minutes
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Figure 30. Graph of Type 1 Subjects Mean Glucose Tracer;Tracee Ratio.
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Table 9. Type 1 Subjects Glucose Metabolism.
LD NPH HD
Baseline Ra 
mg/kg/min
2.15±0.40 2.14±0.18 1.94±0.19
Maximum change 
from baseline Ra 
mg/kg/min
-2.19±0.45 2.53 ±0.36 -2.20 ±0.30
AOC Ra mg/kg 1452.33± 401.61 1461.18 ±288.18 1452.71 ±268.83
Baseline Rd 
mg/kg/min
1.93± 0.42 1.99 ±0.20 2.02 ±0.17
Maximum change 
from baseline Rd 
mg/kg/min
0.29 ±0.46 ** 2.22 ± 0.41 0.83 ±0.31 ***
AUC Rd mg/kg -234.32 ± 350 678 ±138.14 55.74 ±197.5 ***
* Indicates a statistically significant difference between LD and HD. 
** Indicates a statistically significant difference between LD and NPH. 
***Indicates a statistically significant difference between NPH and HD.
Glycerol Metabolism
There was no difference in baseline glycerol Ra between the 3 insulins with 1.47 ± 0.26 
mg/kg/min for LD, 2.61 ±0.72 mg/kg/min for HD and 3.27 ± 0.85 for NPH. The maximum 
change in glycerol Ra from baseline was significantly greater with NPH than HD (p<0.05) 
but not different from LD, nor was LD different from HD with maximum change in glycerol 
Ra being -0.55 ± 0.22 mg/kg/min for LD, -1.09 ± 0.39 mg/kg/min for HD and -2.07 ± 0.67 
mg/kg/min for NPH. There was no difference in the areas over the curve between the 3 
insulins being -143.7 ±211.1 mg/kg/min for LD, -374.7 ± 277.6 mg/kg/min for HD and 
-828.3 ± 439.5 mg/kg/min for NPH.
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Table 10. Type 1 Subjects Glycerol Metabolism,
LD NPH HD
Baseline Ra pmol/kg/min 1.47 ±0.26 3.27 ±0.85 2.61 ±0.72
Maximum change from 
baseline Ra pmol/kg/min
-0.55 ± 0.22 -2.07 ± 0.67 -1.09 ±0.39***
AOC Ra pmol/kg -143.7 ±211.1 -828.3 ±439.5 -374.7 ± 277.6
* Indicates a statistically significant difference between LD and FID.
** Indicates a statistically significant difference between LD and NPH. 
***Indieates a statistically significant difference between NPH and HD.
Figure 31. Graph of Type 1 Subjects Mean Gycerol Rate of Appearance.
Type 1 Subjects Mean Glycerol Rate of Appearance (Ra)
c
5'Sb
I
I
6
ai
O
-60 60 180 300 420 540 660 780 900 1020
Mean H 
■ Mean N 
• Mean L
T im e m in s
NEFA Metabolism
There was no difference in baseline plasma NEFA concentrations between LD and NPH or 
LD and HD, with baseline values for LD and NPH being 1.03 ± 0.25 pmol/1 and 1.03 ± 0.23 
pmol/1 respectively. Baseline concentrations for HD were significantly lower than NPH at 
0.57 ± 0.20 pmol/1 (p<0.04). The maximum change from baseline was greater with NPH 
than HD (p<0.004) but not different between LD and NPH with maximum decrease in
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plasma concentration from baseline being 0.62 ± 0.17 pmol/l, 0.90 ± 0.20 pmol/1 and 0.36 ± 
0.14 pmol/l, for LD, NPH and HD respectively. There was significantly lower area over the 
curve for HD than NPH (p<0.02), but no difference in area over the curve between LD and 
NPH or LD and HD, with values being 262.3 ± 167.0 pmol/1, 537.4 ± 208.9 pmol/1 and 
110.5 ± 126.2 pmol/l for LD, NPH and HD respectively.
Table 11. Type 1 Subjects NEFA results.
LD NPH HD
Baseline NEFA pmol/1 1.03 ±0.25 1.03 ±0.23 0.57 ±0.20 ***
Maximum change from 
baseline NEFA pmol/I
0.62 ±0.17 0.90 ± 0.20 0.36 ±0.14 ***
AOC NEFA pmol/l 262.3 ± 167.0 537.4 ±208.9 110.5 ±126.2***
* Indicates a statistically significant difference between LD and HD.
** Indicates a statistically significant difference between LD and NPH.
***Indicates a statistically significant difference between NPH and HD.
Figure 32. Graph of Type 1 Subjects Mean Plasma Non Esterified Fatty Acid 
Concentrations.
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IGF-1 Plasma Concentrations
There was a significant difference in the baseline between HD and NPH (p<0.02), but no 
difference in baseline between LD and HD or NPH and LD, baseline values being 16.92 ± 
2.32 nmol/1,19.24 ± 2.59 nmol/1 and 16.56 ± 2.51 nmol/1 for LD, NPH and HD respectively. 
There was a significant rise from baseline after dosing with all three insulins (p<0.02 for 
all), with a maximum IGF-1 plasma concentration of 22.36 ± 2.69 nmol/1, 22.72 ± 3.29 
nmol/1 and 22.11 ±2.86 nmol/1 for LD, NPH and HD respectively. However there was no 
difference in plasma IGF-1 concentrations between the three insulins.
Table 12. Type 1 Subjects IGF-1 Results.
LD NPH HD
Baseline IGF-1 concentration nmol/I 16.92 ±2.32 19.24 ±2.59 16.56 ±2.51
Mean IGF-1 concentration nmol/1 17.86 ±2.03 19.52 ±2.84 18.23 ±2.36
Maximum IGF-1 concentration nmol/1 22.36 ±2.69 22.72 ±3.29 22.11 ±2.86
* Indicates a statistically significant cifference between LD and HD.
** Indicates a statistically significant difference between LD and NPH.
***Indicates a statistically significant difference between NPH and HD.
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Figure 33. Graph of Type 1 Subjects Mean Plasma Insulin Like Growth Factor-1
Concentrations.
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IGFBP-1 Plasma Concentrations
All three insulins suppressed IGFBP-1 concentrations. There was no significant difference 
in the baseline or minimum concentrations, nor was there a difference in the change for 
baseline or the areas over the curve. These results are shown in the table below.
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Table 13. Type 1 Subjeets IGFBP-1 Results.
LD NPH HD
Baseline IGFBP-1 
concentration pg/l
36.03 ± 8.07 28.99 ±9.00 31.91 ± 3.87
Minimum IGFBP-1 
Plasma
concentration pg/1
4.14 ±0.64 4.38 ±0.80 3.26 ± 0.66
Maximum change from 
baseline pg/1
31.89 ±7.65 24.61 ±8.52 28.64 ± 3.39
AOC 20528.4 ±4933.6 15842.3 ±7045.4 19244.0 ± 1912.1
* Indicates a statistica ly significant difference between LD and HD.
** Indieates a statistically significant difference between LD and NPH.
***Indicates a statistically significant difference between NPH and HD.
Figure 34. Graph of Type 1 Subjects Mean Plasma Insulin Like Growth Factor Binding 
Protein-1 Concentrations.
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Insulin and insulin detemir
Mean AUC (0-960mins) was 2301.8 ± 505 (nmol/l)*min, 3703.2 ± 230 (nmol/l)*min and 
306.7 ± 94.26(nmol/l)*min for LD, HD and NPH respectively. There was no individual 
difference in the time to reach maximum concentration (Tmax) for the three insulins being 
390 ± 32.8 mins, 515 ± 67.2 mins and 374 ± 74 mins for LD, HD and NPH respectively. 
The maximum concentration (C max) was greater for HD (6160 ± 231.4 pmolf^) than LD 
(4182 ± 1013.4 pmoir^). C max for NPH was 517.7 ± 117.1 pm olf\ The increase in AUC 
and Cmax was less than two-fold however, one subject (Subject 205) dosed with 9 nmol/kg 
insulin detemir had a very high insulin detemir plasma concentration profile.
C-Peptide
All subjects with Type 1 diabetes were c-peptide negative.
Glucagon
The glucagon plasma concentrations did not change after dosing with insulin detemir and 
NPH insulin, and there was no difference between insulin detemir and NPH insulin.
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Type 2 Subjects
Subject demographics
5 male subjeets and 6 female subjects were screened. 3 male subjects and 3 female subjects 
passed screening. Of the 5 subjects who failed screening, 4 failed because their body mass 
index was too high, and 1 failed because of general ill health.
The mean age of subjects was 58.7 ± 2.85 years, they had diabetes for an average of 6.88 ± 
0.41 years and had good control with a mean HbAlc of 6.57 ± 0.35 %. Their weight was 
82.8 ± 8 kg and body fat percentage 33.4 ± 3.59 %.
Plasma Glucose
Subjects arrived for the study day with high blood glucose concentrations having omitted 
their long acting insulin for the previous 24 hours or oral hypoglyeaemic agents for the 
preceding 48 hours. However there was no difference in plasma glucose levels on arrival 
for the study days (9.74 ± 1.79 mmol/1 for LD, 9.09 ± 1.09 mmol/1 for HD and 10.15 ± 2.33 
for NPH). Plasma glucose levels were brought into the clamp range using a tapering dose of 
soluble insulin. There was no difference in the soluble insulin infusion rates on the separate 
dosing days nor was there a differenee in baseline glucose levels at 6.51 ± 0.33 mmol/1 for 
LD, 6.26 ± 0.33 for HD and 6.28 ± 0.37 for NPH. There was no difference in plasma 
glucose concentrations following the administration of insulin being 6.46 ± 0.25 mmol/1 for 
LD, 6.27 ± 0.27 mmol/1 for HD and 6.23 ± 0.35 mmol/1 for NPH. The mean and standard 
differences of the individual coefficient of variation for glucose during the clamp studies 
was 5.19+1.32 % for LD, 6.8+3.08 % for NPH and 5.5+1.26 % for HD.
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Figure 35. Graph of Type 2 Subjects Mean Plasma Glucose Concentrations.
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Glucose infusion rate
There was no difference in the time to start the glucose infusion, maximum glucose infusion 
rate, area under the curve of the glucose infusion or glucose infusion rate after 960 minutes 
between HD and NPH. Comparing HD and LD there was no significant difference in time 
to start the glucose infusion, but the maximum glucose infusion rate was lower with LD 
(p<0.05), the area under the curve was lower with LD (p<0.03) and the glucose infusion rate 
at the end of the study (960 mins) was lower with LD (p<0.01). Comparing LD and NPH 
the glucose infusion rate at 960 minutes was lower with LD (p<0.02), but the differences in 
the other measurement parameters did not reach statistical significance. The time to the start 
of the glucose infusion was 81.5 ± 10.82 mins for LD, 50.8 ± 7.54 mins for HD and 46.0 ± 
10.82 mins for NPH. The maximum glucose infusion rate was 1.93 ± 0.76 mg/kg/min for 
LD, 2.96 ± 0.51 mg/kg/min for HD and 3.29 ± 0.76 mg/kg/min for NPH. The area under the 
curve (ie total glucose infused) was 1130.2 ± 211.2 mg for LD, 1868.5 ± 348.6 mg for HD 
and 1674 ± 211.2 mg for NPH. The glucose infusion rates at the end of the study were 0.89
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±0.13 mg/kg/min for LD, 2,18 ± 0.39 mg/kg/min for HD and 1.79 ± 0.13 mg/kg/min for 
NPH.
Table 14. Type 2 Subjects Plasma Glucose and Glucose Infusion Rate.
LD NPH HD
Mean Plasma Glucose mmol/I 6.51 ±0.33 6 2 8 ± 0 3 7 6 2 6 ± 0 3 3
Time to start of glucose 
infusion mins
81.5 ± 10.82 46.0 ± 10.82 50.8 ±7.54
Maximum glucose infusion rate 
mg/kg/min
1.93 ±0.76* 3.29 ±0.76 2.96 ±0.51
Area under the curve mg/kg 1130.2 ±211.2* 1674±211.2 1868.5 ±348.6
Glucose infusion rate at 960 
mins
0.89 ±0.13 *, ** 1.79 ±0.13 2.18 ±0.39
* Indicates a statistically significant difference between LD and HD. 
** Indicates a statistically significant difference between LD and NPH. 
***Indicates a statistically significant difference between NPH and HD.
Figure 36 Graph of Type 2 Subjects Mean Glucose Infusion Rates.
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Glucose Metabolism
There were no statistically significant differences found between LD, HD and NPH when 
analysed for baseline Ra, maximum change in Ra, AOC Ra, baseline Rd, maximum change 
in Rd or area over the curve Rd, except the maximum change in glucose Ra for LD was 1.58 
±0.13 mg/kg/min which was lower than that for NPH (which was 2.07 ±0.19 mg/kg/min) 
(p<0.04), the maximum change in Ra from baseline for HD was 2.01 ± 0.28 mg/kg/min. 
There were also no differences found using ANOVA to compare the data sets.
Figure 37. Graph of Type 2 Subjects Mean Glucose Rate of Appearance.
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Figure 38. Graph of Type 2 Subjects Mean Glucose Rate of Disappearance.
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Figure 39. Graph of Type 2 Subjects Mean Glucose Ra and Rd.
Type 2 Subjects Mean Glucose Ra & Rd
3.5 1 
-3 -  
2:5-
T T T t i l
- Mean Ra NPH
■ Mean Rd NPH 
Mean Ra HD 
Mean Rd HD
■ Mean Ra LD 
• Mean Rd LD
420  ^ 5io^ 
Time mins
1020
Because of the technical difficulties with our clamp protocol in the changeover from 
intravenous to subcutaneous insulin we also analysed the glucose metabolism data in these 
type 2 subjects from time 60 minutes. When calculated from 60 min the area over the curve 
of suppression of Ra was significantly greater for HD (984 ± 135 mg/kg) compared to NPH 
(535 ± 79 mg/kg)(p<0.04). The area under the glucose Rd curve was 672 ± 255 mg/kg for 
HD and 797 ± 149 mg/kg for NPH (p=NS).
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Figure 40. Graph of Type 2 Subjects Mean Glucose Ra and Rd Expressed as a change from 
T=60 minutes.
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Figure 41. Graph of Type 2 Subjects Mean Plasma Glucose Tracer:Tracee Ratio.
T ype 2 Subjects M ean Plasm a G lucose T racerT racee R atio
0 .16  n
I  I T t  t I I t T t I I t  I T T T I I I  - I ---------------
1-------- 1--------ÔtT 4 -
■ M ean N P H
■ M ean L D  
M ean H D
-180  -1 2 0  -60  0 60  120 180 240  300  360  420  48 0  540  60 0  660  720  78 0  840  90 0  960
Tim e m ins
102
Table 15. Type 2 Subjects Glucose Metabolism.
LD NPH HD
Baseline Ra mg/kg/min 1.64 ±1.99 1.66 ± 0.15 1.67 ± 0.26
Maximum change from 
baseline Ra mg/kg/min
1.58 ±0.13 ** 2.07 ±0.19 2.01 ± 0.28
AOC Ra mg/kg 1015.57 ±102.91 1164.99 ±71.87 1242.29 ±200.76
Baseline Rd mg/kg/min 1.83 ±0.17 1.90 ±0.16 1.83 ±0.24
Maximum change from 
baseline Rd mg/kg/min
0.33 ±0.17 1.32 ±0.49 1.12 ±0.53
AUC Rd mg/kg -70.9 ±153.94 270.3 ±219.65 463.63 ± 355.48
* Indicates a statistical y significant difference between LD and HD.
** Indicates a statistically significant difference between LD and NPH. 
***Indicates a statistically significant difference between NPH and HD.
Glycerol Metabolism
There was no difference in the glycerol Ra at baseline for the three insulins, being 2.26 ± 
0.33 pmol/kg/min for LD, 1.64 ± 0.23 pmol/kg/min for HD and 2.14 ± 0.55 pmol/kg/min 
for NPH. There was also no difference in the maximum change from baseline between the 
three insulins being 0.80 ± 0.26 pmol for LD, 0.72 ± 0.23 pmol for HD and 1.12 ± 0.41 
pmol for NPH. There was however significantly lower area under the curve for HD glycerol 
Ra than NPH glycerol Ra (p<0.04), but no difference in the areas under the curve between 
LD and HD and LD and NPH. The areas under the curve were 321.53 ±271.7 pmol for LD, 
329.34 ± 239.21 pmol for HD and 654.5 ± 345.3 pmol for NPH.
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Table 16. Type 2 Subjects Glycerol Metabolism.
LD NPH HD
Baseline Ra pmol/kg/min 2.26 ± 0.33 2.14 ±0.55 1.64 ±0.23
Maximum change from 
baseline Ra pmol/kg/min
0.80 ± 0.26 1.12 ±0.41 0.72 ± 0.23
AOC Ra pmol/kg 321.53 ±271.7 654.5 ±345.3 329.34 ± 239.21
***
* Indicates a statistically significant difference between LD and HD.
** Indicates a statistically significant difference between LD and NPH. 
***Indicates a statistically significant difference between NPH and HD.
Figure 42. Graph of Type 2 Subjects Mean Glycerol Rate of Appearance.
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NEFA Metabolism
There was no difference between the plasma NEFA concentrations at baseline. Plasma 
NEFA concentrations were more suppressed following HD than ED (p<0.05), but there was
104
no difference between HD and NPH or NPH and LD with minimum concentrations for the 
three insulins being 0.23 ± 0.04 |Limol/l, 0.13 ± 0.03 |imol/l and 0.13 ± 0.05 i^mol/1 for LD, 
HD and NPH respectively. There was no difference in the change from baseline between 
the three insulins nor was there a difference in the areas over the curve.
Table 17. Type 2 Subjects NEFA Results.
LD NPH HD
Baseline NEFA pmol/I 0.55 ±0.12 0.48 ±0.12 0.43 ± 0.06
Maximum change from 
baseline NEFA pmol/l
0.31 ±0.15 0.35 ±0.13 0.30 ±0.09
AOC NEFA pmol/l 75.48 ± 142.0 187.15 ±97.43 137.88 ±156.03
* Indicates a statistically significant difference between LD and HD. 
** Indicates a statistically significant difference between LD and NPH.
Indicates a statistically significant difference between NPH and HD.
Figure 43. Graph of Type 2 Subjects Mean Plasma Non Esterified Fatty Acid 
Concentrations.
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IGF-1 Plasma Concentrations
There was no difference in the baseline, maximum or mean concentrations of plasma lGF-1 
between the three insulins. However there was a significant rise from baseline found in all 
three insulins (p<0.03). The plasma concentrations are shown in the table below.
Table 18. Type 2 Subjects lGF-1 Results.
LD NPH HD
Baseline IGF-1 concentration nmol/1 15.03 ±0.94 13.83 ±0.69 14.44 ±0.97
Mean IGF-1 concentration nmol/1 15.36 ±0.74 14.98 ±0.86 15.59 ±0.92
Maximum IGF-1 concentration nmol/1 18.47 ±1.00 17.82± 1.11 19.92 ± 1.48
* Indicates a statistically significant cifference between LD and HD.
** Indicates a statistically significant difference between LD and NPH.
***lndicates a statistically significant difference between NPH and HD.
Figure 44. Graph of Type 2 Subjects Mean Plasma Insulin Like Growth Factor-1 
Concentrations
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IGFBP-1 Plasma Concentrations
All three insulins suppressed IGFBP-1 concentrations. There was no significant difference 
in the baseline or minimum concentrations, nor was there a difference in the change for 
baseline or the areas over the curve. These results are shown in the table below.
Table 19. Type 2 Subjects IGFBP-1 Results.
LD NPH HD
Baseline IGFBP-1 
concentration pg/l
13.08 ±7.70 22.08 ±16.19 10.73 ±5.63
Minimum IGFBP-1 Plasma 
concentration pg/1
3.8 ±1.75 5.72 ±2.88 2.92 ±1.51
Maximum change from 
baseline pg/l
9.28 ± 6.00 16.36 ±13.33 7.82 ±4.14
AOC 4713 ±3106.1 9033.1 ±7870.3 3976.5 ±1981.8
* Indicates a statistically significant difference between LD and F[D.
** Indicates a statistically significant difference between LD and NPH. 
***Indicates a statistically significant difference between NPH and HD.
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Figure 45. Graph of Type 2 Subjects Mean Plasma Insulin Like Growth Factor Binding
Protein-1 Concentrations.
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Insulin and insulin detemir
Mean AUC (0-960mins) was 1577.6 ± 219.39 nmol, 3131.5 ± 261.92 nmol and 141.8 ± 
31.76 nmol for LD, HD and NPH respectively. There was no individual difference in the 
time to reach maximum concentration (Tmax) for the three insulins being 638.3 ± 86.98 
mins, 625.3 ± 48.49 mins and 565.0 ± 62.57 mins for LD, HD and NPH respectively. The 
maximum concentration (C max) was greater for HD (4996.7 ± 189.84 pmolF^) than LD 
(2660.0 ± 311.02 pmoir^). C max for NPH was 208.8 ± 108.1 pmoH'\ A doubling in insulin 
detemir dose resulted in an approximately two-fold increase in AUC and Cmax.
C-peptide
C-peptide at baseline was similar in each insulin study being 0.46±0.12 nmol/1, 0.49+0.17 
nmol/1 and 0.52±0.14 nmol/1 for LD. NPH and HD respectively. C-peptide suppressed 
following each insulin and there was no difference in this suppression between the insulins 
with minimum c-peptide 0.32±0.08 nmol/1, 0.26+0.07 nmol/1 and 0.27+0.07 nmol/1 
following LD, NPH and HD respectively.
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The plasma concentrations of C-peptide decreased slightly after dosing with insulin detemir 
and NPH insulin in subjects with type 2 diabetes.
Figure 46. Graph of type 2 Subjects Mean Plasma C-Peptide Concentrations.
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Glucagon
The glucagon plasma concentrations did not change after dosing with insulin detemir and 
NPH insulin, and there was no difference between insulin detemir and NPH insulin.
The mean glucagon plasma concentrations were highest in healthy subjects and lowest in 
subjects with type 1 diabetes and subjects with type 2 diabetes were between the two other 
subject groups.
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Combined results
Subjects with diabetes are more insulin resistant than those without, and therefore the data 
from the three groups of subjects (Healthy, Type 1 diabetes and Type 2 diabetes) were 
analysed further by combining the results and comparing the effect of the equipotent doses 
of detemir and NPH. The doses of insulin given for healthy subjects (9 nmol/kg insulin 
detemir and 0.3 iu/kg NPH ) were half that of the doses given to the subjects with diabetes 
(18 nmol/kg insulin detemir and 0.6 iu/kg NPH), in spite of this the doses required similar 
amounts of glucose to be infused to maintain euglycaemia throughout all the groups. It may 
therefore be justified to pool the data as shown below.
Figure 47. Graph of Mean Glucose Infusion Rates for Each Subject Group.
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Plasma Glucose
The plasma glucose thoughout the clamp period (0-960mins) was lower in healthy subjects 
than in those with type 1 diabetes (p<0.0001) or type 2 diabetes (p<0.0001) being 4.94 ± 
0.06 mmol in the healthy group, 6.63 ±0.15 in subjects with Type 1 diabetes and 6.27 ± 
0.22 in subjects with Type 2 diabetes. There was no difference between the plasma glucose
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in the clamp period between the two groups of subjects with diabetes. With plasma glucose 
pooled across the subject groups there was no difference in the plasma glucose for those 
subjects treated with NPH (5.90 ± 0.22 mmol) compared with those treated with insulin 
detemir (5.88 ± 0.21 mmol)(p=NS).
Glucose Infusion Rate
There were no differences in the glucose infusion rates either between the subject groups 
(healthy, type 1, and type 2 subjects), or between the two treatments (detemir and NPH) 
when analysed for total glucose infused, mean GIR, maximum GIR and GIR at 960 mins. 
Table 20. Combined Glucose and Glucose Infusion Rate Data.
Healthy
subjects
Type 1 
subjects
Type 2 
Subjects
Detemir NPH
Area under 
the curve 
GIR, mg/kg
2055.99 ± 
256.95
1776.1 ± 
246.71
1771.5 ± 
196.75
1819.0 ± 
191.95
1936.3 ± 
195.6
Maximum
GIR
mg/kg/min
3.79 ± 0.49 3.63 ±0.51 3.12 ±0.44 3.16 ±0.35 3.89 ± 0.42
Mean GIR 
mg/kg/min
2.12 ±0.29 1.84 ±0.26 1.76 ±0.21 1.83 ±0.20 2.00 ± 0.22
GIR at 960 
mins
mg/kg/min
1.64 ±0.15 1.40 ±0.39 1.98 ±0.20 1.83 ±0.23 1.51 ±0.42
I l l
Figure 48. Graph of Mean Glucose Infusion Rates for Each Insulin from the Combined 
Data from each Subject Group.
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Glucose Metabolism
There were no significant differences found in the effect of the two insulins on glucose Ra 
when compared at baseline, minimum Ra, maximum change from baseline, area over the 
curve Ra or by ANOVA (p=0.06). Baseline Rd was similar for the two insulins but NPH 
had a significantly higher maximum Rd compared with detemir (p<0.04) and also had a 
greater change from baseline (p<0.02). There area under the curve for Rd appeared lower 
for detemir, but the differences were not statistically significant. Using ANOVA the 
differences in the effect on Rd did not quite reach statistical significance p=0.05. Of the 
mean glucose lowering effect of insulin detemir over the 960 minutes 1.39 ± 0.08 
mg/kg/min glucose was infused to overcome Ra (79%) and 0.37 ± 0.07 mg/kg/min glucose 
was infused to overcome Rd (21%), whereas for NPH this was 1.29 ± 0.08 mg/kg/min for 
Ra (65%) and 0.68 ± 0.10 mg/kg/min for Rd (35%)(p<0.001).
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Table 2 1 . Combined Glucose Metabolism Data.
Detemir NPH
Baseline Ra mg/kg/min 1.87±0.11 1.95 ±0.08
Minimum Ra mg/kg/min -0.23 ± 0.09 -0.19 ±0.12
Maximum change from baseline Ra mg/kg/min 2.09 ±0.14 2.14±0.12
AOC Ra mg/kg 1375.3 ± 111.5 1282.2 ±84.1
Baseline Rd mg/kg/min 1.97±0.10 1.97 ±0.08
Maximum Rd mg/kg/min 3.18 ±0.25 3 ^ 8 ± 0 JT
Maximum change from baseline Rd mg/kg/min 1.21 ±0.25 1.90 ±0.29
AUC Rd mg/kg 367.38 ± 159.9 625.4 ± 140.4
Figure 49. Graph of Mean Glucose Ra and Rd for each insulin from the combined data from 
each subject group.
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Figure 50. Bar charts showing the relative proportion of glucose lowering effect from effect 
on glucose Ra and glucose Rd of each insulin using data combined from the three subject 
groups.
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Figure 51. Pie chart showing the overall mean proportion of effect of each insulin on
glucose Ra and Rd using data combined from the three subject groups.
Pie chart showing overall mean effect of Detemir on Glucose Ra and Rd
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Chapter 4 
Discussion
In the 1990s the link between metabolic control and development of microvascular 
complications was firmly established by the diabetes control and complications trial research 
group (DCCT). The DCCT was a study in 1441 subjects with type 1 diabetes. They were 
randomised to either intensive control (with basal bolus regime and strict targets) or 
conventional treatment. Those in the intensive group had a mean HbAlc of 7.1% whereas 
those in the conventional treatment group had an HbAlc of 9.0%. There was a lower rate of 
complications in the intensive group with a reduction in: the risk of retinopathy of 45%, 
development of microalbuminuria by 35% and clinical neuropathy by 60%. For every 10% 
reduction in HbAlc (ie a reduction in HbAlc from 10% to 9%) there was about 35% risk 
reduction of retinopathy, 25-44% risk reduction for nephropathy and 30% risk reduction for 
neuropathy. However the risk of hypoglycaemia increased threefold in the intensive 
treatment group. The United Kingdom Prospective diabetes study research group (UKPDS) 
looked at intensive versus conventional treatment in patients with type 2 diabetes, and 
showed risk reduction in microvascular endpoints, myocardial infarction, cataract extraction, 
retinopathy and albuminuria.
These studies were large, well-controlled and highly regarded and demonstrated the 
importance of good control for reducing the risk of complications. As a result of these 
studies the objective now in the treatment of diabetes is not the avoidance of multiple 
injections but the imitation of normal physiology.
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Figure 52. Diagram of the Physiological Plasma Insulin Secretion Profile. 
Physiological serum insulin secretion profile
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In people without diabetes insulin is released constantly from the pancreas at a “basal level” 
with boluses of insulin released at meal times to cover additional prandial requirements. 
Bolus (mealtime) insulin release from the pancreas limits hyperglycaemia after meals by an 
immediate sharp rise and a peak at 1 hour (Bell et al., 1996). At first insulin regimes were 
felt not to be satisfactory because the meal time bolus was with regular insulin. This insulin 
when injected subcutaneously existed in hexameric form and therefore must dissociate into 
dimers and monomers before it could be absorbed into the capillary circulation 
(Cunningham et al, 1955). Conventional “short acting” or regular insulin had onset of 
action about 1 hour after injection and peak action at 2-4 hours (Howey et al, 1994). Thus 
patients were advised to inject insulin around 30 minutes before a meal (an instruction that 
was rarely adhered to), and to take snacks between meals to compensate for prolonged 
hyperinsulinaemia, which can lead to hypoglycaemia (Barnett, 2001). Rapid acting 
analogues were designed to mimic the prandial release of insulin. They have fast absorption 
times with onset of action after 20 to 30 minutes and peak action at about 1-2 hours, leaving 
a shorter duration of action than regular insulin (Howey et al, 1994) and as such more
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closely mimic physiological insulin release in response to meals. All the pivotal studies 
involving several thousand patients with Type 1 and Type 2 diabetes showed significant 
reductions in postprandial glucose excursions using the rapid acting insulin analogues 
compared with human soluble insulin (Owens et al, 2000, Anderson et al 1997a, Anderson 
et al, 1997b and Kang et al, 1991). This was entirely expected based on the more rapid 
absorption and higher peak insulin levels demonstrated in earlier phase studies. These 
registration studies, however did not show a significant improvement in glycated 
haemoglobin, although there was a significant improvement in patient satisfaction (Barnet, 
2001). The latter was primarily related to the fact that patients could take their rapid acting 
insulin analogue immediately prior to eating a meal, rather than half an hour before. 
Furthermore the incidence o f hypoglycaemia was reduced in those using rapid acting insulin 
analogues compared to those using regular insulin as their bolus (Brunelle et al, 1998, 
Holleman et al 1997).
Because these analogues did not normalise blood glucose control as hoped attention was 
turned to basal insulins. It was recognised that little or no improvements in basal insulins 
had occurred since the 1930’s when the concept of crystalline insulins as a method of 
protraction was conceived. It is accepted that these longer acting insulins do not imitate the 
basal insulin production from the pancreas, but rather have peaks of action after around 6-8 
hours and had variable absorption, resulting in huge differences in daily basal insulin levels 
(Home, 1999). Blood glucose variability correlates with mean glycaemic exposure and risk 
of hypoglycaemia (Moberg et al, 1994), and also with mortality (Muggeo et al 2000). 
Somogyi (1959) observed that the blood glucose and glycosuria of diabetic patients often 
showed wide fluctuations even when both carbohydrate content of the diet and insulin dose 
are unchanged.
With conventional crystalline suspensions of insulin some of this can be explained by poor 
mixing techniques, with variations in the actual concentration of insulin injected varying in 
one study from 5-214% (Bolli and Owens, 2000). Studies have shown that fluctuations in 
absorption rate are the main cause for unpredictable insulin activity, accounting for as much 
as 80% of the variability in the action of NPH insulin or insulin lente (Guthrie, 2001).
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Laurizten et al (1979) injected subjects with radiolabelled NPH insulin over a 12 day period, 
they found that absorption varied greatly from full to only 19% on some doses. Chen et al
(2003) also observed large variations in absorption of NPH insulin after subcutaneous 
injection with 50% of the original dose of insulin found at the injection site for around 12 
hours on one day and around 96 hours on another in the same patient. Luzio et al (2003) 
also describes large variations in insulin absorption rates with 50% absorption between 7 
and 18.2 hours for NPH and 10.2 and 42 hours for glargine. There is also considerable 
variation in the absorption of NPH depending on the site of injection (Lauritzen et al, 1982), 
and the time of day that that site is used (Chen et al, 2003).
The drive now was to design an insulin to mimic the secretion of basal insulin in healthy 
subjects so to suppress glucose production between meals and overnight. Renewed interest 
in prolonging the duration of action of insulin has led to developments along different 
strategic routes. The expectation that proinsulin would increase basal insulin concentrations 
was short lived because of concerns on cardiovascular safety that arose from clinical studies 
(Owens et al, 2001). Proinsulin’s metabolite, des (64,65)-human proinsulin had an even 
shorter period of action than NPH insulin and was discontinued (Owens et al, 2001). 
Surprisingly, the strategy to slow absorption and clearance by strengthening hexameric 
interactions in the form of cobalt (Ill)-insulin complex also proved unsuccessful (Burge et 
al, 1997). However, increase of the isoelectric point of insulin from 5.4 towards neutrality 
thereby causing precipitation or crystallisation at the site of injection, delays absorption, and 
prolongs the effect of insulin (Markussenet al, 1987). The first acid soluble extended action 
insulin analogue made by this method was Novosol Basal GlyA21, ArgB27, ThrB30-NH2- 
insulin (Jorgensen et al, 1989), which was discontinued because of escalating dose 
requirements (reduced bioavailability) possibly associated with local inflammatory reactions 
at the site of injection. On the basis of the same concept, a di-arginylinsulin analogue 
known as insulin glargine was developed that had a much slower and more reproducible rate 
of subcutaneous absorption than NPH insulin (Owens et al, 2000), resulting in slower onset 
and extended hypoglycaemic effect (Lepore et al, 2000, Heineman et al 2000). An 
additional phenol molecule bound to the hexamer of crystalline insulin glargine might 
further contribute to its protracted action.
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Insulin glargine is the first of these long acting insulin analogues to make it to the market, 
being launched in 2002. Plasma glucose and insulin concentrations vary less between 
patients when insulin glargine is used compared to ultralente insulin (Lepore et al, 2000, 
Scholtz et al 1999). Comparison of insulin glargine with NPH insulin in isoglycaemic 
clamp studies shows that a bolus subcutaneous injection of NPH insulin (0.3iu/kg) produces 
a definite peak effect within 3-6 hours, before returning to baseline at 16 hours. By contrast 
insulin glargine plateaus at a concentration 2-3 times lower than NPH within 6-8 hours, 
remains essentially unchanged for 24 hours (Heinemann et al, 2000) and is unaffected by the 
site of injection (Owens and Barnett, 2000). In studies comparing insulin glargine with 
NPH as part of a basal bolus regime, subjects using insulin glargine had a greater reduction 
in fasting blood glucose (Pieber et al, 2000, Ratner et al, 2000, Rosenstock et al, 2000, 
Raskin et al, 2000), less variability in blood glucose (Rosenstock et al, 2000, Raskin et al, 
2000), a lower frequency of hypoglycaemia (predominantly nocturnal) (Pieber et al, 2000, 
Ratner et al, 2000) and a fall in glycosylated haemoglobin (Pieber et al, 2000). However 
injection site pain which is negligible in the NPH group is experienced in 6.1% with insulin 
glargine, presumably because of the acidic pH (4.0) of insulin glargine (Raskin et al, 2000). 
Insulin glargine has also been compared to NPH insulin in patients with type 2 diabetes. 
Both insulins were given at bedtime in poorly controlled circumstances in which insulin 
naïve patients were allowed to continue oral agents (Yki-Jarvinen and Westerbacka, 2000). 
Overall glycated haemoglobin improved to the same extent in each group, however there 
was a lower frequency of nocturnal hypoglycaemia in the glargine treated group. Similarly 
in patients with type 2 diabetes changing from NPH once or twice daily to glargine at 
bedtime, there was a lower risk of nocturnal hypoglycaemia and equivalent glycaemic 
control (Rosenstock et al, 2001). In these studies no differences in doses were recorded, but 
either no weight gain (Rosenstock et al, 2001), or less weight gain with insulin glargine 
(Wang et al, 2003), than with NPH.
Insulin detemir is a long acting soluble insulin analogue, with a 14 C fatty acid chain 
attached to position B29 and omission of the amino acid residue at position B30 of the 
human insulin molecule (Brunner et al, 2000). The fatty acid residue associates with free
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fatty acid binding sites on albumin in interstitial fluid and plasma (Kurtzhals et al, 1995) 
developing an equilibrium between free and albumin bound analogue. Only the free fraction 
of insulin detemir permeates the capillary wall entering the blood stream and binding to 
albumin again. To reach peripheral target tissues (muscle and adipose) free insulin detemir 
must again pass the capillary wall. The principle of protraction is based on slow release 
from albumin and strong self-association at the injection site (Havelund et al, 2004, Brunner 
et al, 2000). Insulin detemir uniquely among the long acting insulin analogues does not 
form a precipitate at the site of injection and this property has been considered to be of key 
importance in eliminating a potential source of variability (Lindholm, 2002). It is also likely 
that plasma albumin binding may buffer the effect of short duration changes in the depot 
absorption rate, thereby limiting the pharmacodynamic variability (Kurtzals, 2004). This 
favourable action was found in a study reported by Heise et al (2004) and Bott et al (2003) 
compared the pharmacokinetic, pharmacodynamic profiles and within subject variability of 
NPH, detemir and glargine in patients with Type 1 diabetes. Subjects received 4 identical 
doses of an insulin on four different dosing days, 18 subjects were randomised to each 
insulin. In this study reproducibility of the glucose infusion rate curves were analysed and it 
was found that the probability of reproducibility was worst for NPH insulin, followed by 
glargine and that detemir had the most reproducible curve. The coefficient of variation for 
pharmacodynamics as observed by glucose infusion rate and pharmacokinetics as assessed 
by insulin concentration area under the curve was significantly lower with detemir than NPH 
and glargine. This favourable action may result in lower frequencies of unpredicted hypo or 
hyperglycaemia. A study reported by Pieber et al (2002) looking at duration of action, 
pharmacodynamic profile and between subject variability of insulin detemir in subjects with 
type 1 diabetes, found a linear dose response relationship for pharmacokinetic and 
pharmacodynamic properties of detemir. It reported a longer duration of action at a dose of 
0.4u/kg (20 hours) than NPH at a dose of 0.3iu/kg (13 hours). They also reported less 
between subject variation.
Capillary endothelial cells in adipose and muscle limit the transfer of insulin detemir from 
the circulation into the extravascular extracellular space (Havellund et al, 2004), whereas in 
the liver the sinusoids are lined by highly fenestrated epithelial cells, between which there
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are large gaps. The sinusoids also have no basal lamina. Because of the large gaps in the 
endothelial cell layer and the absence of a continuous basal lamina, no significant barrier 
exists between blood plasma in the sinusoid and the hepatocyte plasma membrane (Ross, 
2003). Insulin detemir can therefore pass freely to this “space of Disse” (the perisinusoidal 
space) Gray, 1973, Reichen, 1999). Hepatocytes will be freely exposed to insulin detemir 
possibly resulting in a greater effect of this insulin analogue on the liver than on peripheral 
tissue.
Insulin detemir’s binding properties may provide an alternative theory for insulin detemir’s 
apparent hepatoselectivity. The albumin binding properties of insulin detemir have been 
extensively studied using an immobilised human serum albumin (HSA) preparation 
(Kurtzhals et al, 1995 and 1997). The binding constant of insulin detemir for HSA was 
determined to be 2.4 x 10  ^ M'^ at 23°C and 1.0 x 10  ^ M'^ at 37°C in this assay system. 
Based on this binding constant, insulin detemir is estimated to be 98.4% bound in plasma 
(37°C, 0.6mM albumin), which is consistent with the above determined plasma protein 
binding (98.8%) of insulin detemir (Kurtzhals et al, 1995). We can see therefore that 
detemir has a higher binding affinity to albumin at colder temperatures. Core body 
temperature is higher than that at the periphery (Kim et al, 1998). This may mean that a 
higher proportion of detemir is free (that is not bound to albumin) in the core (ie at the liver) 
whereas in the periphery (that is in adipose and muscle tissue) detemir will be more tightly 
bound to albumin and less will pass through the capillary wall to act on target cells. This 
may explain why detemir’s hepatoselective effects in people with type 2 diabetes is more 
difficult to demonstrate, as these people tend to have a higher proportion of their adipose 
tissue centrally (that is intra-abdominal fat deposits) where temperatures are more likely to 
resemble core body temperatures, and thus detemir will be less bound to albumin and more 
freely able to pass the capillary wall and act on target adipose cells.
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Why is it important for an insulin to act more on the liver than in the periphery?
Glucose metabolism:
As discussed earlier the brain almost exclusively utilizes glucose as a source of energy 
(Cryer 1997). The brain has high energy requirements (required to maintain the ionic 
gradient across nerve membranes, critical for maintenance of brain activity) estimated at 
approximately 1 mg/kg/min corresponding to about lOOg glucose per 24 hours, however it 
has low energy reserves (enough for only a few minutes), and is unable to synthesize 
glucose (Bolli, 1998). Intricate mechanisms to protect the supply of glucose to the brain 
have therefore evolved. Only the liver and the kidney are able to release glucose. This 
release results from the presence of glucose-6-phosphatase in these organs which liberates 
glucose into the bloodstream (Bolli and Fanelli, 1999). It is generally believed that the liver 
makes the major quantitative contribution during this state, whereas the kidney has a minor 
role, except during prolonged starvation, when it is estimated that the kidney may contribute 
almost half of glucose production (Bolli 1998, Cahill et al,1966, and Cahill, 1970).
Blood glucose is sensed in the brain (Frohman and Nagai, 1976, Ritter et al, 1981, Borg et 
al, 1995), pancreas(Taborsky et al, 1998) and liver (Connolly et al, 1996), each of these 
organs is involved in the counter-regulation response to low blood glucose in healthy 
subjects. A fall in blood sugar concentration that may occur in the postabsorptive state leads 
initially to a reduction in insulin secretion, by direct action of glucose on p-cells of the islets 
of Langerhans (Cryer 1997, Bolli, 1998). This leads to a reduction in the plasma insulin 
concentration in the portal circulation, and therefore a reduction in the suppression of 
hepatic glucose output (or a rise in hepatic glucose output). If the blood glucose continues 
to drop counter-regulatory hormones are stimulated and released.
As discussed earlier in the introduction section on glucose metabolism, all counter 
regulatory responses to hypoglycaemia increase hepatic glucose output either directly alone 
or in combination with an indirect effect by the stimulation of lipolysis (Bolli, 1998), some 
also decrease peripheral glucose uptake. In normal physiology these defence mechanisms
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are appropriate as insulin is released into the portal circulation and has its first effects at the 
liver, and the liver is essential in the production of glucose to support brain metabolism 
(Bolli, 1998). In insulin dependent diabetes no insulin is released by the pancreas 
exogenous insulin is administered by subcutaneous delivery, it circulates peripherally first, 
and is controlled by pharmacokinetics, with peak actions occurring 1 to 8 hours after 
injection (Bolli, 1998). The insulin profile does not resemble physiological insulin profiles 
of a normal 24 hour day, and is unable to respond to changing insuhn need (Amiel, 1998, 
Cryer et al, 2003). In this situation the liver is relatively underinsulinised and peripheral 
tissue over insulinised. In the event of hypoglycaemia, the first line of counter regulation 
(that is a decrease in insulin release) is not possible, insulin levels remain inappropriately 
high suppressing hepatic glucose output, increasing peripheral glucose uptake and inhibiting 
lipolysis. Further counter regulation has evolved to exert itself primarily at the liver, 
suppression of hepatic glucose output is thus easily overcome since in these circumstances 
as the liver is relatively underinsulinsed however the peripheral over insulinisation presents 
a more difficult obstacle, and therefore it could be argued that greater counter regulation has 
to occur to prevent a further fall in plasma glucose and maintain the brain’s glucose supply. 
This may cause later hyperglycaemia as a result of the sustained release of counter 
regulatory hormones and their prolonged duration of action may be a factor in the overall 
deterioration in glycaemic control seen in patients with frequent hypoglycaemia.
Hypoglycaemia is a common problem encountered in the treatment of diabetes. In one 
study on 411 patients with type 1 diabetes (Pramming et a l, 1991) patients had 1.8 episodes 
of mild hypoglycaemia per patient per week, and 0.027 episodes of severe hypoglycaemia 
per patient per week. Others have suggested people with diabetes have an average of 2 
episodes of symptomatic hypoglycaemia a week (Reichard, 1991, Macleod et al, 1993), and 
an estimated 2-4% of deaths of people with diabetes are attributable to hypoglycaemia 
(Laing et al, 1999). Socially this also causes problems to patients with diabetes with around 
three times the percentage of people with type 1 diabetes being refused car insurance than 
those without diabetes (Songer et a l, 1991). In the DCCT and UKPDS studies rates of 
severe hypoglycaemia were higher for a given HbAlc in conventionally treated patients than 
those on intensive treatment regimes, however those on intensive treatment regimes were
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more likely to have more frequent hypoglycaemia. Hypoglycaemia seems to be the price to 
be paid for improving rates of progression to complication.
Duration of diabetes is associated with decreases in the hormonal response to 
hypoglycaemia (Bolli et al., 1983). This can lead to a vicious circle of hypoglycaemia 
causing impaired physiological responses to hypoglycaemia, causing reduced awareness to 
hypoglycaemia, causing increased vulnerability to further episodes and thus more 
hypoglycaemia.
Lipid metabolism and weight gain:
The counterregulatory hormone response to insulin acts primarily by increasing glucose Ra. 
This is less effective against exogenous insulin, which acts mainly to increase glucose Rd. 
Thus an insulin analogue exerting greater effects on the liver than the periphery has the 
potential to reduce hypoglycaemic episodes and may reduce weight gain through less 
snacking to avoid hypoglycaemia. Peripheral hyperinsulinaemia increases peripheral 
glucose uptake and lipogenesis and decreases lipolysis contributing to the weight gain 
associated with insulin therapy (Andreani, 1999). Kruszynska et al (1985) investigated the 
effects on carbohydrate metabolism of peripheral insulin delivery compared to portal insulin 
delivery. They found in rats that hepatic glycogen concentrations are lower in rats receiving 
insulin into the systemic circulation compared to those rats receiving insulin via the portal 
circulation. Others have shown that sensors in the liver to increased intracellular ATP 
concentrations affect eating behaviour via signals transmitted via vagus afferents from the 
liver to the brain (Mayer, 1991, Freidman, 1995, Langhans, 1996). Although the control of 
eating behaviour remains a highly complex and controversial subject with many factors 
having been shown to influence it. Nonetheless recent large-scale clinical trials comparing 
detemir and NPH provide support for the theory that by acting in a more physiological way 
detemir has advantages over NPH. These trials have shown that nocturnal hypoglycaemic 
episodes are reduced and weight gain is lower with insulin detemir when compared to NPH 
insulin (Russell-Jones et a l , 2002, De Leeuw et al 2002, Vague et al 2003).
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IGF-l/GH secretion:
In patients with type 1 diabetes growth hormone levels have been found to be raised 
throughout the day with increased frequency and amplitude of pulsatility and exaggerated 
responses to a wide variety of stimuli (Tamborlane et al, 1979). Although there is a marked 
increase in growth hormone, IGF-1 levels are at the low end of normal or are suppressed 
(Tan et al, 1986). IGF-1 levels are not normalised with intensive therapy or by maintainence 
of good control (Amiel et al, 1984). Delivery of insulin via the portal system influences 
hepatic IGF-1 production. In rats intraperitoneal insulin given to mimic portal insulin 
increases IGF-1 mRNA expression and systemic IGF-1 levels (Russell-Jones DL, 1992), 
Griffen et al (1987) also provided evidence that insulin delivered via the portal circulation is 
more effective than systemic insulin at restoring IGF-I levels in diabetic rats. 
Subcutaneously delivered insulin leads to unphysiological low portal insulin and this may 
explain why, despite intensive s.c. insulin therapy, circulating IGF-I levels in diabetic 
patients remain either low or at best low normal (Rudolf et al 1981). IGF-1 itself has a 
negative feedback effect on GH secretion. It seems likely that in IDDM and NIDDM the 
low level of IGF-1 is sensed at the hypothalamus/pituitary level, and GH is hypersecreted 
(Simpson et al, 1998). This will lead to a distorted GH/IGF-1 axis with raised GH and 
inappropriately low IGF-1. This elevated GH contributes to the insulin resistance and 
causes the “dawn phenomenon” which is difficult to control (Fowelin, et al, 1991, Periello et 
al, 1990). Changes in GH levels have been implicated in the development of microvascular 
complications, particularly retinopathy but also nephropathy (Chiarelli et al, 2000). Low 
levels of circulating IGF-1 have also been implicated to be associated with neuropathy 
(Migdalis et al, 1995). Some authors have suggested that relative underinsulinisation of the 
liver may play an important role in the development of microvascular complications 
(Sonksen et al, 1993, Wurzberg et al 1995, Janssen et al, 2000). It is possible therefore to 
speculate that an insulin that has greater effect at the liver may be associated with reduced 
frequency of microvascular complications.
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Is detemir hepatoselective?
From other studies; A study reported by Russell-Jones et al (2004) compared once daily 
nocturnal injection of detemir and NPH in a 6 month multicentre randomised controlled 
trial. They found that treatment for 6 months with insulin detemir resulted in slight lowering 
of HbAlc, lowering of fasting plasma glucose, less fluctuation in blood glucose levels 
especially at night, less nocturnal hypoglycaemia in the last 5 months of treatment and a 
relative decrease in weight in comparison to the group treated with NPH. Vague et al (2003) 
reported the efficacy and tolerability of detemir compared to NPH in a basal bolus regime 
using asp art as the bolus insulin. They also reported that detemir had similar metabolic 
control judged by HbAlc but found a lower within subject variation in fasting blood 
glucose, a flatter and more stable blood glucose profile during the night, a lower risk of 
hypoglycaemia, a relative decrease in weight gain and a good safety profile. De Leeuw et 
al (2002) reported a study using NPH or detemir as a twice daily basal regime, and using 
aspart as the bolus insulin. Again it was found that detemir had similar glycaemic control 
over 12 months, significantly lower risk of hypoglycaemia and a significant and favourable 
weight reduction in comparison to NPH. Pieber et al (2004) reported a study using a basal 
bolus regime with aspart as the bolus insulin and twice daily basal injections of detemir or 
NPH. The NPH was given at breakfast and bedtime, in one detemir arm detemir was given 
as the NPH (ie breakfast and bedtime) and in the other it was given at breakfast and at 
suppertime. Compared to NPH detemir provided significantly lower fasting plasma glucose 
in both arms, significantly lower within subject variation in both arms and less weight gain. 
Thus suggesting that detemir may be administered more flexibly than NPH. Home et al
(2004) reported a similar study with type 1 subjects randomised to receive their basal insulin 
in a basal bolus regime as either NPH morning and bedtime, detemir morning and bedtime 
or detemir 12 hours apart. Again they found detemir produced significantly lower fasting 
plasma glucose, lower within subject variability, lower nocturnal hypoglycaemia, less 
weight gain and flexible administration. Haak et al (2004) reported a study with type 2 
individuals using a basal bolus regime with aspart as the bolus insulin, and twice daily NPH 
or detemir. They found lower risk of hypoglycaemia, less weight increase and similar 
glycaemic control. Hermansen et al (2004) compared an analogue basal bolus regime of
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twice daily detemir (morning and bedtime) with aspart as the bolus insulin to a human 
insulin regime of twice daily NPH (morning and bedtime) with actrapid as the bolus insulin. 
Subjects had type 1 diabetes and were randomised in an open label trial for 18 weeks. They 
found the analogue regime lowered HbAlc more than the human insulin regime and caused 
less nocturnal hypoglycaemia.
From this study: The equivalence in glucose infusion rate profiles is of key importance 
when interpreting the comparative effects of two insulin preparations on glucose Ra and 
glucose Rd. Insulin exhibits a different proportion of action at each of these sites at varying 
concentrations. In diabetic patients (Brown et al 1978) and in diabetic dogs (Issekutz et al 
1974) it has been demonstrated that peripheral infusion of insulin at low rates of 
0.5mU/kg/min without euglycaemia reduces hepatic glucose output without increase in 
glucose Rd. Thus at low concentrations of insulin the majority of the glucose lowering 
effect occurs by suppression of glucose Ra, with only a small effect on glucose Rd. At 
higher concentrations the majority of action occurs by glucose Rd once glucose Ra has 
effectively been completely suppressed (Sonksen and Sonksen, 2000). Therefore results 
from studies that compare the effects of two insulin preparations on glucose Ra and Rd 
where the glucose infusion profile is not equivalent must be treated with caution as the 
difference in effect may be purely related to dose.
In this study we have demonstrated in healthy subjects that 9nmol/kg insulin detemir is 
equipotent to 0.3 iu/kg NPH, with a very similar time action profile, we have also 
demonstrated in subjects with Type 1 diabetes that 18nmol/kg insulin detemir is equipotent 
to 0.6 iu/kg NPH, with a similar time action profile There were small but significant 
differences in the effect of this dose of insulin detemir on glucose Ra and a lesser non­
significant effect on glucose Rd compared to the equipotent dose of NPH suggesting a 
greater effect on liver than on peripheral tissue. In the group with type 1 diabetes there were 
also small but significant differences in the effect of this dose of insulin detemir on glucose 
Rd but no measurable differences in the effect on glucose Ra (which at this dose of insulin 
is almost completely suppressed) suggesting NPH has a greater effect on the periphery than 
an equipotent dose of insulin detemir.
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The reduced effect of insulin detemir on peripheral tissues was confirmed by the 
measurements of NEFA concentration. The suppression of NEFA concentrations by insulin 
detemir was less than with an equipotent dose of NPH, both in healthy subjects and to a 
lesser extent in those with type 1 diabetes (the effect in subjects with type 1 diabetes was 
further clouded by apparent although non statistical differences at baseline). It has been 
suggested that insulin’s suppressive effect on peripheral lipolysis with a decrease in NEFA 
concentrations is an important signal mediating an indirect effect of insulin on glucose Ra 
(Bergman, 2000). The demonstration in this study, that detemir has greater effect on 
glucose Ra but less effect on NEFA concentration than an equipotent dose of NPH insulin, 
suggests that the action of detemir on glucose Ra is independent of NEFA delivery to the 
liver.
In type 2 subjects the results are more difficult to determine. There was great inter­
individual variation in the response to the insulins. There were also technical difficulties 
with interpreting the clamp results as both the Ra and Rd for each individual fell after the 
baseline bloods had been taken and the injection given at time 0 reaching a nadir at around 
60 minutes, suggesting that the patients were not at steady state at the start of the clamp. 
This is probably a result of the technical difficulties associated with the study design of 
controlling the blood glucose using intravenous insulin and converting to subcutaneous 
insulin at time 0 even though the delayed absorption of these insulins would mean that 
subjects would effectively be without insulin for a short period at the beginning of the study. 
It is not clear why the effect of this is more pronounced in the subjects with Type 2 diabetes. 
However when analysed using time 60 minutes as baseline there was greater effect on 
glucose Ra with insulin detemir than the equipotent dose of NPH, and a small (although not 
significant) reduction in the effect on glucose Rd for detemir compared to NPH.
Looking at the effect on lipid metabolism in subjects with type 2 diabetes findings are 
similar to those in subjects with type 1 diabetes and healthy subjects, in that there was less 
suppression of glycerol Ra with insulin detemir compared with NPH (although this 
difference again was clouded by apparent although non statistical differences at baseline)
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and less effect on NEFA suppression, although the latter did not reach statistical 
significance. There were no measurable differences in these insulins effects on IGF-1 or 
IGFBP-1 in subjects with type 1 or type 2 diabetes.
When analysed together as a combined set the data from these 19 subjects show the glucose 
lowering effect of these insulins are not different. Insulin detemir suppresses hepatic 
glucose output equivalently but has less effect on peripheral glucose uptake. This further 
supports our hypothesis.
The clinical implications of an insulin that may act in a more hepatoselective way are 
exciting. As described above by acting more physiologically detemir may give protection 
from profound hypoglycaemia and may reduce the frequency of hypoglycaemic episodes. 
Studies so far indeed indicate this reduced hypoglycaemia risk. This is of great importance 
to patients in whom the fear of hypoglycaemia is often a barrier to improved control and 
thus lowered risk of micro and macrovascular complications. There have been no studies 
with long enough follow up to determine the long term benefits of detemir with respect to its 
potential effects on reducing microvascular complications as a result of its differential effect 
on IGF-1. These advantages may only become apparent with decades of use of this insulin.
Limitations of this work:
This study had many limitations, lack of resources and man-power meant that it was not 
feasible to attempt to achieve more than 6 analysable sets of data in each group of patients. 
This in itself meant that we performed nearly 1400 hours of euglycaemic clamping. With 
low subject numbers it was difficult at times to demonstrate statistically significant 
differences in our results although similar trends ran throughout our findings.
Constraints of metabolic study:
Metabolic studies often provide such results with day to day intra-individual variation 
making interpretation more difficult. Also the calculations used in these studies rely on
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assumptions to determine glucose Ra and glucose Rd, and data entered in these calculations 
undergoes a smoothing program which may result in important differences being minimised. 
As described above it is of utmost importance that the glucose infusion rate profiles be as 
equivalent as possible for comparison between two insulins (ie their equipotency must be as 
near as possible) for interpretation of differences to be truly due to differences in insulin 
action and not merely differences due to dose. We were exceptionally fortunate that in the 
healthy subjects the glucose infusion rates were inseparable and thus the small differences 
that we found could be truly attributed to effect rather than dose.
These differences appear small but if each dose results in 10% greater action at the liver than 
the periphery as demonstrated in the healthy subjects in this study, then the cumulative 
effect over the years of administration may be clinically relevant.
The results from the two groups of patients with diabetes has been more difficult to 
interpret. The studies were technically much more difficult, in order to avoid “hangover 
effect” from any other long acting insulin, patients were asked to omit their long acting 
insulin from 24 hours prior to the study. However we know from data presented above that 
NPH has highly variable absorption, and therefore it is possible that some of the NPH 
previously injected was still acting thus accounting for the greater intra-individual variation 
in results in this group of patients. Also lowering blood glucose after presentation on the 
study day was not without difficulties, as rapid lowering meant difficulties arose during the 
baseline period and looking at the data from both diabetic groups it is clear that subjects 
were not at steady state at baseline or for the 30-60 minutes following subcutaneous 
injection as the calculations clearly show falls in both Ra and Rd during this time period.
The type 2 patient subject group also shows considerable variation. The very nature of this 
group of patients is variable given that they represent a spectrum of diabetes from insulin 
resistance to decreased insulin production. Therefore as a group their results are more 
variable. This means that the small differences we demonstrated in other groups in this 
study were more difficult to demonstrate in this group of patients. Also this group consisted 
of some patients with higher abdominal girth (although this was not actually measured) and
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as previously discussed this may lead to a greater effect of detemir on central deposits of 
adipose tissue and thus less relative effect on the liver. Given these considerations it may 
have been prudent to increase the numbers of subjects studied in the type 2 group, or 
controlled for other variables such as abdominal girth.
In conclusion this study shows that when compared to an equipotent dose of NPH, detemir 
has a greater effect on glucose metabolism in the liver than in peripheral tissues. This 
reduced effect of insulin detemir on peripheral tissues was confirmed by less of an effect on 
NEFA concentrations than NPH. This suggests that this insulin analogue has the potential to 
imitate the normal insulin gradient, thus mimicking normal insulin physiology more closely 
than any other insulin currently available. This may mean that this insulin has therapeutic 
advantages over other currently available insulin preparations.
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